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Intimal hyperplasias is the most significant factor limiting vascular intervention therapy, with 
an incidence of between 30-50% following coronary or femoral angioplasty, and between 10 
and 30% of coronary artery saphenous vein bypass grafts (CABG). Extensive research over 
the past decade into the pathology and pharmacological treatment of this condition has not 
yet provided a reasonable solution to the multifactorial etiology of restenosis. Patients with 
metabolic syndrome have a higher risk for cardiovascular disease and mortality, and those 
with Diabetes mellitus Type II are at an even greater risk post intervention. It is our 
hypothesis that obesity has a significant impact on the pathology in the neointima, 
specifically with respect to the development of intimal hyperplasia (IH). In addition, the pro-
inflammatory nature of obesity is known to elicit an increased inflammatory response that 
may contribute to the increase in stenosis. 
Methods: 
This study examines the histopathological response to injury following both balloon 
angioplasty and endovascular stenting in the Zucker rat, a model that allows interpretation of 
the role of obesity as well as progressive glucose intolerance and hyperinsulimaemia. Lean 
and obese Zucker fatty rats and Zucker diabetic fatty rat (ZDF) were subjected to balloon 
injury with or without stenting. The development of IH, along with the histological response 
to injury was analyzed. 
Results: Following balloon angioplasty alone, the obese group displayed a greater degree of 
IH than the lean group, whereas the ZDF group unexpectedly was largely devoid of a 
hyperplastic response. There were very few inflammatory cells at the 21 day time point 
defined in this study. There was a high level of C-reactive protein staining in the obese group. 
In the stented groups, there was very little variation in the degree of IH between the three 
genotypes, with only a slight increase observed in the obese group. Inflammatory cells were 
more evident on the stented groups.  Evidence of increased endothelial glycocalyx following 
balloon injury was also demonstrated. 
Conclusion: 
Our results confirmed the role of obesity in the development of IH. In the stented groups, the 
degree of IH was controlled by the presence of the endovascular stent. The mean intimal 
thickness between the wires (that is from the lumen to the IEL) was (129.8 ± 60.0µm, 120.3 ± 
33.2µm and 141.4 ±100.8µm for the ZFR-F, ZFR-L and ZDF rats respectively; p=N.S). The 
intimal thickness after 21 days following stent deployment over the three groups was non-











was (129.8 ± 60.0µm, 120.3 ± 33.2µm and 141.4 ±100.8µm for the ZFR-F, ZFR-L and ZDF 
rats respectively; p=N.S). The intimal thickness over the wires (that is from the lumen to the 
stent wire, but excluding the stent area) was non-significant (79.5 ± 66.3µm, 96.4 ±58.3µm 
and 95.6 ± 97.6µm). The twenty-one day time point proved to be optimal for the analysis of 
IH, but was not ideal with regard to inflammation. The prominent endothelial glycocalyx 
observed post angioplasty proved to be an interesting and novel finding, which may help to 













 Introduction and Background 
1.1 Introduction 
Cardiovascular disease (CVD) remains the leading cause of death in the world today (Table-1). 
Histological studies have shown that the precursors of heart disease begin in adolescence and evolve 
over decades (4). The arteries most commonly affected are the coronary arteries that emanate from the 
aorta and supply the heart muscle with oxygenated blood. Focal thickening of the intima layer by 
proliferating smooth muscle cells (SMC) and the accumulation of lipids or fatty streaks form the basis 
of an atherosclerotic lesion. These lesions may develop into fibrous plaque capsules, which typically 
rupture exposing the blood to a thrombogenic surface resulting in thrombus formation (5). These 
lesions cause vascular occlusion restricting the blood flow through the coronary arteries supplying the 
heart muscle, and eventually resulting in myocardial infarction (MI) (Fig-1). 
According to the Australian Institute of Health, Russia has the highest death rate from CVD, and 
Japan has the lowest incidence, most likely due to their low fat, high fish diet (6). In America, CVD 
has remained the leading cause of death since 1990, with 40% of deaths resulting from heart disease 
and with more than 1 million percutaneous coronary interventions (PCI) being performed annually.  
According to the World Health Organization (WHO) 11,8 million people died of CVD in 2005 and 
this is estimated to rise to 20 million in 2015.  
Table 1 Top ten causes of death in high & low income countries (7). 
                             
The pathophysiological and molecular mechanisms driving these diseases are a focus of this thesis in 
an attempt to gain a better understanding of the inter-relationship between CVD and metabolic 
syndrome (MS). MS refers to a cluster of risk factors with a high correlation to the prevalence of 











CVD places a major health and economic burden on the world, especially in developing countries. In 
low to middle income countries, health care budgets are sub-optimal, making it imperative to use the 
limited resources effectively, to make primary health care available to the whole population. 
According to the American Heart Institute, health care costs are estimated at around $475.3 billion in 
the USA for 2008. This figure includes both the cost of health care as well as the loss of productivity 
burden. In the UK this figure was £30.7 billion in the same year (9).  
The death rate from CVD is escalating in developing nations. The incidence of diabetes mellitus (DM) 
is expected to double between 2005-2050, and is one of the major risk factors for CVD. The reduction 
of this epidemic is largely dependent on prevention of such risk factors (9) (Table 2). 
                                       
Figure 1 Coronary arteries, providing blood supply 
to the heart together with vascular sections showing the 
development of disease to the point of occlusion (10). 
1.1.1 Metabolic Syndrome 
MS or syndrome X, as it was previously known constitutes a set of metabolic changes that increase the 
risk of CVD and diabetes mellitus type II (DM2). One out of every five people are affected by MS 
(11). The main features of MS include obesity, DM2, hypertension and elevated LDL levels (12). MS 
is diagnosed when there is central obesity plus any two of the factors mentioned (Table 2).  
The incidence of DM and MS has risen to alarming rates worldwide. A quarter of the world’s 
population presents with MS and this state is therefore driving CVD. In the USA alone, 20-25% of 











The two most significant factors of MS are obesity and insulin resistance (IR). Hereditary factors, 
physical inactivity, ageing and a pro-inflammatory state contribute to the etiology of this disorder.  
Early diagnosis and treatment is therefore an essential component of heart disease prevention (13).  
The International Diabetics Federation (IDF) has drawn up a universally accepted diagnostic tool that 
is simple to use in clinical practice (Table 3). In addition to these criteria, they have described 
additional parameters for research purposes, which are also implicated in MS (Table 4). 
Table 2 Criteria for the Diagnosis of MS. (14) 
 
Table 3 The new IDF definition of MS 
 
The above parameters can all be measured during the diagnosis of MS and the related disorders. One 
explanation for IR is that, due to the increase in free fatty acids (FFA) in the blood of obese 
individuals, they are utilized as an energy source instead of the glucose present in the muscle tissue, 
leading to a build up of excess glucose in the blood. This leads to increased insulin output from the 
Beta cells of the pancreas as the body tries to compensate in order to cope with the excess glucose.  
Eventually the pancreas stops producing insulin leading to glucose intolerance and severe and life 











Table 4 Metabolic Measurements For Research (13). 
                           
The excess accumulation of adipose tissue in the abdominal region in obese individuals also results in 
a pro-inflammatory state, impacting on vascular pathology (15). Elevated body mass index (BMI), 
which compares body weight to height, has an abrogating effect on CVD. It is measured by dividing 
body weight by the square of the patient’s height. BMI is frequently used to identify weight problems 
such as obesity (14). However, it is the measurement of waist circumference or waist to hip ratio, 
which is a more accurate indicator of a metabolic syndrome profile than BMI. A waist measurement 
>102cm in males and >88cm in females indicates the presence of MS (14).  
Statins have been successfully administered as treatment for the symptoms of MS. They have anti-
inflammatory effects and lipid lowering properties, as well as protective effects on the vascular wall 
by lowering oxidative stress. They are reported to increase availability of nitric oxide (NO) by this 
mechanism and thereby improve endothelial function. Endothelial cell (EC) dysfunction involves an 
impaired vasodilatory response and changes in the cell to matrix or cell-to-cell interactions (5, 16). 
The reduction of plasma cholesterol is also known to decreases the risk of plaque formation (16). 
As a combined therapy, rosuvistatin and fenofibrate, a drug known to reduce low-density lipoprotein 
(LDL) and triglycerides (TG), have been used to treat more than one factor of MS, and have shown 
improvements in lipid & metabolic values (12, 17). 
The normal artery wall consists of three cell layers, the tunica intima, tunica media and the tunica 
adventitia (Fig-2). The lumen of the vessel layer is lined with a single layer of endothelial cells resting 
on a basement membrane made up of extracellular matrix (ECM) components, namely collagen, 
laminin and proteoglycans (PG). The media consists of concentric layers of SMC with alternating 
bundles of elastic fibres, forming distinct bands or lamellae. The SMC respond to stimuli from the 
endothelium in response to contraction and dilation. The adventitia is composed of a collagen matrix, 
vasa vasorum (a network of blood vessels), lymphatic system, elastin and nerve fibres. The internal 
elastic lamina (IEL) separates the tunica intima from the tunica media and the external elastic lamina 












Figure 2 Histological structure of the normal artery wall (19) 
The proliferation of SMC and their secretion of ECM components in the inner lining of the 
vasculature is referred to as intimal thickening, and is known to pre-dispose arteries to the 
development of atherosclerotic lesions. This occurs in arteries from birth and progresses throughout 
life, particularly in the coronary and carotid arteries (18). 
The early histopathological changes are less easily monitored but due to excess FFA in the blood of 
obese individuals, fatty streaks or lipid droplets accumulate beneath the endothelium. These vascular 
lesions may consist of macrophages, foam cells, T 
lymphocytes, connective tissue elements and debris 
and place the patient at significantly increased risk of 
cardiovascular complications (19) (Fig 3).  
1.1.2 Obesity 
Obesity is fast becoming a global health concern as 
the number of obese individuals is rising steadily, 
with estimated costs to the health care system in the 
USA of $92 billion in 2002 (14). The lack of 
physical activity combined with high fat and high 
sugar diets is the primary cause of this disorder. 
Abdominal obesity can be used to define obesity. 
The degree of obesity correlates to the degree of IR, 
which in turn correlates to the extent of intracellular 
stores of triglycerides (TG). A BMI > 30kg/m2 meets 
the criterion for obesity in adults, but this problem is 
not confined to adults only. There has been a 
threefold increase in obesity in children under 20 
years of age from 1980-2007.  Obesity is associated with several health complications including DM, 
IR, MS and CVD. A large proportion of the increased risk, due to obesity can be attributed to an 
Figure 3 A Schematic representation of the 












inflammatory process. Fat mass behaves much like an endocrine organ, secreting adipokines and FFA, 
which influence lipid metabolism and insulin sensitivity. The metabolic and immune pathways are 
inter-connected, as the prevalence of obesity over-activates the immune system, creating a chronic 
low-grade inflammation or a pro-inflammatory state (14). 
1.1.3 Hyperglycemia, Insulin Resistance and glucose Intolerance 
The term, hyperglycemia refers to an elevated blood sugar. High blood glucose levels have been 
implicated in tissue and organ damage as well as degradation of the endothelial glycacalyx layer 
(EGL), lining the vasculature (21). The EGL is a network of membrane-bound PG and glycoproteins 
covering the endothelium on their luminal surface (22). The disruption of this glycocalyx layer results 
in increased reactive oxygen species (ROS) and raised levels of hyaluronic acid (HA) in the blood 
circulation, which leads to dysfunction of the EC (21) (Fig-4). 
 
Figure 4 The effect of hyperglycemia on ROS and Endothelial dysfunction (16) 
Impaired glucose tolerance refers to the association with a pre-diabetic state of dysglycemia. It is 
associated with insulin resistance and an increased risk of CVD, and it occurs some time before DM2 
manifests itself (23). 
The inability of the body to adequately respond to insulin in the liver, muscles or adipose tissue, is 
referred to as IR. IR in fat cells results in a decrease in the effect of insulin and therefore increased 
hydrolysis of stored TG. Increased mobilization of stored lipids elevates FFA in blood plasma. IR in 
the muscles causes reduced glucose uptake with excess glucose being stored as glycogen. IR in liver 
cells results in impaired glycogen synthesis and failure to deal with elevated levels of glucose. These 
three forms of insulin resistance all contribute to increased blood glucose levels (23). 
The production of insulin by the beta cells of the pancreas regulates glucose levels in the blood stream. 
IR, however, results in excess accumulation of glucose in the blood, triggering the need for more 
insulin production. The result is both hyperinsulinemia and hyperglycemia. This can lead to 
destruction of the beta cells (24). Insulin resistance is believed to be the origin of MS and type II DM 
and is present long before the onset of DM. At diagnosis, approximately 50% of beta cell function has 











There have been more than 15,000 publications in recent years regarding insulin resistance and CVD. 
Research on Pima Indians from SW Arizona, revealed that they appear to have a protective 
mechanism against heart disease in spite of being overtly obese. In humans the association between 
obesity and the sympathetic nervous system (SNS) has been reported, and confirmed by studies on 
animal models (25). In the Pima Indians there is no correlation between SNS activity and insulinemia. 
This could explain how the inability of insulin to activate the SNS in response to obesity may 
contribute to the low incidence of hypertension. Pima Indians have a greater percentage of obesity but 
a lower percentage of hypertension and CVD. Their SNS activity level is 20-30% lower than the white 
population. Thus a low SNS activity level would be desirable, as it appears to be protective against the 
development of hypertension (25).  
1.1.4 Diabetes Mellitus-Type II 
Type II diabetes, previously referred to as non-insulin-dependent diabetes mellitus (NIDDM), 
resulting from impaired glucose tolerance, has become a worldwide epidemic. The health care costs 
for individuals suffering from diabetes, is escalating not only in the Western world, but globally. 
Research in this field is ongoing to gain a better understanding of the pathogenesis of this disease and 
to formulate more effective drugs or combinations of drugs. Type II diabetes is the most common 
form of diabetes, accounting for 90-95% of the disease in Western societies. There is a relative insulin 
deficiency combined with defects in insulin action, with 80% of patients being obese or with a history 
of obesity. The complications of this disease include micro vascular and macro vascular chronic 
disorders (26). 
The excess glucose concentration in the blood, or hyperglycemia, in DM2 is associated with oxidative 
stress and causes early functional changes to the endothelium. This endothelial dysfunction may be 
detected by measuring change in microcirculation using flow mediated vaso-dilation and could be 
useful in diagnosis and treatment prior to the development of angiopathy in DM. In a review by Skhra 
et al. it was concluded that the use of antioxidants reduced formation of ROS, confirming that 
oxidative stress plays a role in endothelial dysfunction before the development of angiopathy in DM 
(16).  
There is an increased susceptibility to atherosclerosis in the presence of hyperglycemia, and an 
increase in the generation of ROS. Known histological changes are an increase in wall thickness, 
impaired architecture and increased permeability of basement membrane in DM (16). 
The coagulation cascade and fibrinolysis is activated in the presence of excess glucose, which is 
confirmed by thrombin generation (21). These factors all contribute to the escalation of vascular 
disease that is associated with DM. 
Atherosclerosis and CVD occur at an earlier age in diabetic patients. Management of all the metabolic 
risk factors, cholesterol & TG levels, blood pressure and obesity as well as a low fat controlled diet 












Lipid profiles together with clinical assessment are needed to diagnose MS. Lipoprotein 
macromolecular micelles transport fats around the body. They are classified into five groups according 
to size. From the largest to smallest they are: i) Chylomicrons ii) Very low-density lipoproteins 
(VLDL) iii) Intermediate density lipoproteins (IDL) iv) LDL and v) High density lipoproteins (HDL). 
Lipoproteins are made up of a water-soluble outer layer of phospholipids, cholesterol and 
apolipoproteins, with TG and cholesterol esters in the centre (Fig-5) (27). 
Hypercholesterolemia and increased LDL levels are 
associated with an increased risk of CVD. Monitoring of 
these parameters is a general guideline for evaluating 
the risk of heart disease. TG are components of VLDL, 
which play an important role in metabolism and supply 
of energy but do not dissolve in the blood. An increase 
in TG is an indicator for higher risk of atherosclerosis, 
and is often accompanied by low HDL, high LDL levels 
and IR. Excess calorie intake is stored in fat cells as TG 
and released by hormones as required. High LDL and 
TG together with a low HDL is a typical profile of an 
individual presenting with MS and is a predictor for the development of atherosclerosis (28). 
1.1.6 Hypertension 
Hypertension or raised blood pressure, is one of the important criteria in the diagnosis of MS and 
commonly found together with DM. In the presence of IR, the pancreas is stimulated to produce more 
insulin. An increase in insulin, is in turn, associated with an increase in blood pressure (12).  
1.1.7 Atherosclerosis 
The intimal layer of arteries is defined as the endothelial cell surface to the medial region and is 
composed of two sub-layers. The inner layer contains an abundance of PG and SMC, both synthetic 
and contractile, occurring as single cells rather than layers. The second layer is termed the 
muscoelastic layer due to the presence of elastin fibres and collagen with SMCs in closely associated 
layers (29). Intimal thickening is understood to be areas of healthy intima, into which SMC migrate 
and proliferate resulting from mechanical stress due to variations in blood flow, or flow shear stress 
(FSS). These areas may develop into atherosclerotic lesions and can be referred to as “atherosclerotic-
prone” areas. They are also referred to as intimal cushions, focal intimal hyperplasia, muscoelastic 
plaque or diffuse intimal fibrosis. Atherosclerotic lesions as they are now commonly known, were 
previously referred to as “fatty streaks” or “fibrous plaque” (30) and are described by the WHO as 
“atheroma”.  












Figure 6 The key players in the early development of Atherosclerosis. EC injury allows LDL to penetrate the 
sub-intimal space. This is phagocytosed by macrophages, differentiated monocytes from the blood stream, 
which ultimately become foam cells and die, releasing their contents into the necrotic core. Increased SMC 
proliferation and EC apoptosis follows. (33) 
The centre of an atheroma is made up of foam cells and lipid droplets surrounded by a cap of SMC 
and a collagen-rich matrix. These lesions can result in thrombus formation and acute vascular 
occlusion, thereby restricting the blood flow through the coronary arteries resulting in a MI. This may 
be caused by two factors, endothelial erosion or rupture of the plaque, resulting in the exposure of 
thrombotic material from the core of the plaque to the blood surface (5). The progression of the 
vascular disease to the point of atherosclerosis can be seen in (Fig-7).  
The EC layer is vital as a non-permeable barrier and plays a role in protecting SMC against 
proliferation and migration. These cells modulate homeostasis and thrombolysis and synthesize 
growth factors such as fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and 
transforming growth factor (TGF). EC damage results in secretion of ECM proteins and the formation 
of neointimal hyperplasia (NIH). The greater the degree of endothelial damage, the greater the intimal 
thickening (31). The EC plays a pivotal role in the formation of atherosclerosis as retention of LDL in 
the intima initiates inflammation (29). 
Subsequent oxidation of LDL results in activation of EC. Their functions include mediation of 
vascular tone, control of inflammation and immune response, thrombo-resistance and membrane 
barrier permeability (29). Plaque rupture is thought to involve inflammatory cytokines, coagulation 











glycocalyx layer found on the surface of vascular EC, is suggested to be the primary event in the 
formation of atherosclerosis. In 2008, Noble et al. proposed that the glycocalyx lining the endothelium 
is the first line of defense against atherosclerosis in DM and MS and suggested that sites of low shear 
stress resulted in decreased NO, an anti-atherogenic factor release, due to glycocalyx disruption (32). 
The glycocalyx will be discussed in detail later in this section. 
Atherosclerosis is an inflammatory disease, associated with raised levels of inflammatory cytokines. 
Plasma markers such as C-reactive protein (CRP) and macrophage chemotactic protein (MCP-1) are 
considered predictors for atherosclerotic risk and 
restenosis following PCI (33). Inflammatory cytokines, 
tumor necrosis factor alpha (TNF-alpha) and Interleukin 
(IL) 6 are up regulated following injury (5). TNF alpha 
levels were increased 100,000-fold for at least 6 days 
following injury and inhibition of TNF alpha has been 
shown to improve vascular recovery (34). The results 
from the JUPITER ‘Justification for the Use of Statins 
in Primary Prevention: an Intervention Trial Evaluating 
Rosuvastatin’ trials in 2008 confirmed that high 
sensitivity-C-reactive protein (Hs-CRP) levels, were 
indeed strong predictors of atherosclerosis and 
cardiovascular disease (35). Inflammation is associated 
with atherosclerosis, restenosis, IR and MS. 
Local and systemic inflammatory mediators are critical during the development of atherosclerotic 
plaque. The inflammatory cells found within the plaque, are activated by cytokines, chemokines, 
hormones and growth factors, inducing a pro-inflammatory state involving adipose tissue and the liver 
(36). Adiponectin is a cytokine-like hormone secreted by adipose tissue, which has been found to be 
protective in obesity related MS and CVD.  Okamoto et al suggest that adiponectin has anti-
inflammatory effects on macrophages, whereby T cell recruitment is suppressed. The low levels of 
adiponectin present in patients with MS, DM and obesity, result in the recruitment of T lymphocytes 
that are key contributors to an immune response in atherosclerosis (37). The mechanism of this can be 
attributed to a mutation in the adiponectin gene (I164T), which is associated with hypo-
adiponectinemia resulting in disturbed secretion into the circulation. This may contribute significantly 
to MS (38). 
Immunosuppressant or anti-inflammatory agents can be employed to treat atherosclerotic lesions. 
Immunosuppressant agents block activation of T-cells and SMC proliferation as well as prevent 
intimal lesions and restenosis following angioplasty (5). Anti-inflammatory agents enhance NO 
production and fibrinolysis (5). (See therapy section below) 
Figure 7 Chronology of the 











1.2 The formation of Intimal Hyperplasia (IH) Following 
Coronary Intervention 
1.2.1 Background 
Injury to the vascular wall by balloon angioplasty, results in cellular proliferation, migration and 
inflammation. Release of inflammatory cytokines and growth factors follows. A critical phenotype 
change occurs in vascular SMC, changing from a contractile to a synthetic phenotype. This enables 
them to proliferate and migrate from the media to the intima and to produce PG and collagen in this 
layer. One of the signal transduction mechanisms, which control the formation of IH in diabetic states, 
is protein kinase C and mitogen activated protein kinase. Endothelial dysfunction also plays an 
important role with decreased NO production. The degree of hyperplasia is proportional to the extent 
of the injury induced by the balloon inflation and the transmural pressure applied (39) 
The formation of IH is primarily then a combination of two factors, SMC proliferation and ECM 
formation. Nikkari et al. described the ECM gene being a “late event” following balloon injury to the 
rat carotid, with some genes expressed in the intima, while others were expressed in both intima and 
the media (40). In the process of arterial wall repair after endothelial denudation, there is an increase 
in elastin and tropoelastin, in a controlled manner in SMC occurring at the end of their proliferation 
phase (41).  
In a study by Frank Sims in 1989, the structural features of coronary arteries of 10 different species 
were compared (18). The study pertained to the structure of the IEL, and suggested that discontinuities 
or disruptions of the IEL were structural abnormalities that were present at birth and progressed 
throughout life. Animal models were found to repair such irregularities of the IEL, while humans did 
not, and this forms the basis of intimal thickening due to an increase of SMC in the intimal 
compartment. The internal mammary artery (IMA), also known as the internal thoracic artery (ITA), 
in humans appears to be the ideal vessel, since it does not have these disruptions in the IEL, and does 
not develop significant atherosclerosis. It also has endothelial cells closely associated with the IEL that 
forms a continuous inner lining for the arterial wall. In contrast to animal models, Sims found that 
human coronary arteries showed substantial intimal thickening with an incomplete endothelialized 
luminal surface. Their findings suggest that the structural differences in arterial walls among different 
species, could explain the variations of advanced coronary disease. Animal models compared were 
baboon, pig, sheep cattle, rabbit and rat coronary arteries (18). 
IH is formed over a period of days following injury in animals and over six months in humans. 
Virmani et al. described this variable vascular response in rabbit and porcine models compared to 
human. In animal models, the first 24-hour period involved platelet and neutrophil migration to site of 
injury. After three days, neutrophils and macrophages were evident. By day seven, SMC proliferation 
and migration had occurred, and by day twenty-eight, foreign body giant cells and SMC in a PG, 











inflammatory process evident from day 1-30. At six months the presence of SMC within a matrix was 
visible (42). 
The delayed healing that occurs in human arteries can be explained by the fact that there is an 
underlying diseased state of atherosclerosis whereas the experimental balloon injury done on animals, 
is typically done on young healthy animals, without an existing inflammatory state (42). 
1.2.2 The Role of the ECM 
The ECM plays a critical role in the development of IH. It is made up of PG (versican, biglycan, 
decorin), HA and collagen types I and III. PG and HA are synthesized by SMC and are involved in 
regulation of vascular permeability, lipid metabolism and thrombosis. During the formation of the 
neointima, in response to balloon injury, the ECM modulates cell proliferation and migration, growth 
factor expression and remodeling. In spite of the fact that the ECM constitutes 50% of the volume of 
restenosis lesions, SMC proliferation and neointimal inflammation have been in the forefront of 
research into the development of IH (43).  
In human coronary arteries that have undergone endovascular stenting, neointimal versican and HA 
stain strongly positive, co-localizing with smooth muscle actin (SMA) in SMC. In stents implanted for 
longer than 18 months, decorin has been reported to stain strongly. SMC density and restenosis is 
reduced in stents implanted for longer than 18 months. Scott et al. suggested that the later stages of in-
stent restenosis are caused by enhanced ECM rather than by SMC proliferation (44).  
The pattern of wound healing follows a path very similar to restenosis, which is a re-occurrence of 
intimal thickening following vascular intervention. Initially there is a thrombotic and acute 
inflammatory reaction, followed by a granulation phase, which involves macrophage infiltration, 
myofibroblast ingrowth and angiogenesis. An early ECM begins to form, composed of fibrin, 
fibronectin, HA and versican. HA provides the matrix for mesenchymal cells to migrate and promotes 
cell proliferation. It also supplies feedback regulation to growth factor synthesis. Versican binds to HA 
and creates viscoelasticity to healing tissues (45). HA then begins to degrade with reabsorbtion of a 
portion of collagen III, while synthesis of collagen I, decorin and biglycan takes place. This is 
followed by wound contraction and healing within two weeks. The response to a coronary stent in 
humans, does not show complete healing until 18 months after deployment (43). The importance of 
the ECM in the development of IH, is not clearly understood, however research in the past decade has 
unraveled the role played by the endothelial glycocalyx and its associated PG, and shown them to play 
a critical role in maintaining endothelial cell integrity and it’s part in mechanotransduction. The PG in 
the ECM appear to play an important role in the control and development of IH (46). 
1.2.3 The Endothelium 
The endothelium is a single cell layer lining the entire vascular system, with a multitude of dynamic 
functions that impact on the behavior of the adjacent cells in the vessel wall. It is involved in 











production and secretion of growth factors, and mechanotransduction by sensing changes in blood 
flow and shear stress. It is involved in the production of NO, essential to the proper functioning of the 
endothelium. EC are sensitive to the formation of ROS, which, in excess, can cause dysfunction of the 
EC (21). Disruption of the EC membrane by mechanical or biological damage, or endothelial 
dysfunction in CVD associated with diabetes or atherosclerosis, triggers a chain of inflammatory 
events in an attempt to promote healing (47). 
1.2.4 Shear Stress and the Endothelium 
Shear stress (SS) is the force that is exerted when the blood flow acts on the endothelial surface, and is 
frequently referred to as FSS or wall shear stress (WSS). The endothelial functions are mediated by 
blood flow, which acts via endothelial mechanotransduction (48). The mean WSS varies across 
species, between different arteries as well as along the arterial tree. In humans WSS varies between 
(0.3-1.3 Pa) compared to that in rats of between (5 and 10 Pa) (49). The glycocalyx is part of the 
mechanism of sensing and transducing shear stress (50), and it is of interest that the atherosclerotic 
prone regions have a reduced glycocalyx layer (51). Gouverneur et al. showed that shear stress 
actually stimulates endothelial glycocalyx production, which could explain the thinner EGL at arterial 
bifurcations exposed to low FSS (50), and therefore play a critical role in determining where vascular 
pathology originates (48).  
High SS is beneficial in structural remodeling of the artery wall. It stimulates the release of NO, which 
is necessary for endothelial function. Davies et al have ascertained that endothelial 
mechanotransduction is unlikely to be the only mechanism of mechanotransduction (48). Normalizing 
SS at sites of vascular intervention would be a logical approach. 
 
Figure 8 Schematic image of a PG monomer, consisting of a core protein and GAG side chains. (57) 
Proteoglycans and IH play an integral role in vascular repair of the arterial wall following injury by 
PCI and have been shown to accumulate in atherosclerotic lesions. They have been targeted in many 











been well described (17, 52-54). PG are composed of a protein core with one or more 
glycosaminoglycan (GAG) side chains. There are five types of GAG chains, chondroitin sulfate (CS), 
heparan sulfate (HS), dermatan sulfate (DS), keratan sulfate (KS) and HA. HA is the exception of the 
GAG family in that it is not bound to a protein core (22). The basic structure of a PG can be seen 
below and variations in side chains give them their individual characters (Fig-8).  
The distribution of matrix PG is a determinant of intimal structure and patency in atherosclerosis and 
restenosis (55). Merrilees et al. compared the distribution of PG distribution in the intimas of coronary 
arteries (CA), saphenous veins (SV), internal ITA and radial arteries (RA). Results showed that the SV 
and CA were very similar in their PG profiles, with high levels of sub-endothelial versican and 
biglycan, but low levels of decorin. The ITA displayed high levels of decorin and this vessel gave 
better long-term patency. The radial artery, which is predicted to have better patency than the SV, has 
an even distribution of all three PG, versican, biglycan and decorin, does not the accumulate in the 
sub-endothelial layer. The differences in PG distribution in the intima, correlate strongly to established 
differences in patency between the SV and the ITA (55).  
The IH region consists of ECM components including PG, elastin and collagen of which PG make up 
80% of the IH within 3 months of injury. These components modify the biological functions of, and in 
the artery wall, such as viscoelasticity, lipid metabolism, permeability and thrombosis (56). The key 
PG are discussed below together with their importance and role in neointimal formation.  
1.2.4.1 Perlecan  
Perlecan is a PG that contains both HS and CS side chains. It is found in the basement membrane of 
several cell types and is critical for vascular repair and a regulator of homeostasis (53). Secreted by 
vascular smooth muscle cells (VSMC), perlecan is a potent inhibitor of SMC proliferation due to its 
capacity to bind FGF-2. As one of the prominent PG, perlecan is part of the regulation of IH and an 
absolute necessity to the prevention of occlusive thrombosis with its ability to bind to anti-thrombin 
III. The removal of perlecan has been shown to cause a decrease in the ability of EC to reduce intimal 
thickening. The HSPG are also involved in lipid metabolism, as lipoprotein-lipase interacts with EC in 
a HS dependent fashion as well as, possibly by modulating the charge density of the lipid as it passes 
through the EC barrier (53). In the rat model, there is a 2-fold increase in perlecan transcription within 
2-4 weeks of balloon injury (40).  
1.2.4.2 Versican   
Versican is composed of CSPG. The synthesis and secretion of CS is carried out by SMC, and it is a 
major arterial PG (56). The prominence of CS containing versican in primary, restenotic and 
atherosclerotic lesions is evidence of its importance as a matrix PG. It accumulates in intimal lesions 
where it is involved in trapping of LDL (40). The proliferation and migration of SMC is facilitated in 











1.2.4.3 Biglycan  
Biglycan, composed of DSPG and CSPG, is one of the three matrix PG (together with versican and 
decorin) that are important determinants of the vessel wall structure and pathology.  They are small 
leucine rich PG associated with restenotic lesions (55). Biglycan is found in the intimal and medial 
regions of such lesions and is present after 9 months to 18 months following stenting (43). Its function 
is not yet well understood. 
1.2.4.4 Decorin  
Decorin is a small collagen-associated PG made up of CS and DS, both synthesized primarily by SMC 
(56). It presents in a more fibrous intima or fibrous caps of atherosclerosis. It has been found in the 
intima of the ITA and the RA correlating to improved patency following artery grafting, and could 
have a protective role against the build up of IH (55).  
1.2.4.5 Hyaluronan   
Hyaluronan, also referred to as HA, is the exception of the PG, as it does not contain a protein core 
and it is non-sulfated. It is strongly demonstrated in vessels with vascular disease and only weakly in 
normal vessels (57). HA forms the basis of the pericellular matrix, and is anchored to the cell surface 
by the CD44 receptor (Fig-9). PG attach themselves to the HA structure thereby increasing its 
stiffness. It is substantially reduced in atherosclerotic lesions of diabetics, while in non-
atherosclerosed arteries it is increased. SC and DS in contrast are increased in diabetics. This suggests 
a different pathological process in the macro 
vascular disease in diabetes to that of 
atherosclerosis (58). HA is involved in cell 
adhesion, proliferation and migration and 
possibly in inflammatory processes (3).  
Versican & HA are present in high amounts in 
the restenotic arterial tissue after balloon injury, 
and their synthesis is modulated by growth 
factors PDFG and TGF-beta (57). This 
combination of PG and collagen matrix enables 
tissue to resist shear deformation (3). The 
matrix into which mesenchymal cells migrate is 
provided by HA, which promotes proliferation and supplies feed back regulation of growth factors. It 
is still present after 18 months following stent deployment (59).  
The Endothelial Glycocalyx and Intimal Hyperplasia 
The entire vascular endothelial surface is lined with a fine, carbohydrate-rich layer, approximately 20 
nm-5 µm in thickness, made up of PG and glycoproteins, the EGL. GAG side chains are covalently 
attached to a core protein (Fig-10). The PG are said to be the “backbone”, connecting the glycocalyx 
to the endothelium (22). Although, first discovered some 40 years ago by Luft, with the use of electron 
Figure 9 Hyaluronan chains attached to the cell 











microscopy, its composition and function still remain unclear. Much research has been done in the last 
10 years, as its importance in vascular pathology has become appreciated (22). As a major component 
of vascular tissue, PG are involved in lipid metabolism, vascular permeability, homeostasis and 
thrombosis. Wight et al. stated that “the accumulation of PG in intimal lesions is a hallmark of early 
and late atherosclerosis” (60). The glycocalyx thus forms an integral part of the vasculature and the 
loss or reduction of this delicate structure must have detrimental effects on the functions of the 
endothelium. PG are synthesized by both EC and SMC, and play an important role in migration, 
adhesion, and proliferation of SMC.  
The polyanionic nature of the components of the gylcocalyx, result in a net negatively surface charge. 
HS, CS and DS are amongst these PG, as well as HA. HS comprises 50-90% of the EGL in the 
vasculature, and contains anti-coagulative species thus preventing thrombus formation (60, 61).  The 
three main protein core families of HSPG found on EC are transmembrane syndecans, membrane 
bound glypicans and basement matrix associated perlecans (61). In addition to glycoproteins & PG 
soluble proteins, originating from the bloodstream or the endothelium, may give added stability to the 
mesh like glycocalyx, particularly HA. It is known that the glycocalyx layer is very delicate and its 
properties are affected by enzymatic removal of any components (22). 
 
Figure 10 Schematic representation of the Glycocalyx Structure, consisting of a core protein with GAG side 
chains attached (64). 
Van den Berg et al. suggested that damage to the glycocalyx layer played an important role in 
atherosclerosis and demonstrated that the carotid arteries in mice, which are prone to atherosclerosis, 
have a reduced glycocalyx, and therefore a disturbed flow pattern (51). Noble et al hypothesize that 
the disruption of the glycocalyx is the first step prior to atherothrombotic disease (32) and suggest that 
disturbed blood flow manifests itself as “shear stress”, first detected by the glycocalyx which then 











proposed that the damage to the lumenal area results in changes such as exposure of the EC to 
thrombus and inflammation, leading to atheroma. 
In a study by Yao et al. on the effect of SS on the endothelium, it was shown that the glycocalyx was 
necessary for the alignment of SMC and their response to SS. It is known that after 24 hrs of laminar 
flow, EC will align in the direction of flow with reduced proliferation. In this study, the removal of HS 
GAG from the cell surface using the enzyme heparinase III, revealed that EC were unable to align 
under laminar flow conditions and proliferated as if there was no flow present. It was demonstrated 
that HSPG establish themselves in a peripheral pattern and accumulate above cell-cell junctions, 
which could reduce the shear gradient that cells undergo during conditions of flow (54).  
The Starling principle can be described as the balance of hydraulic and colloidal osmotic forces across 
the capillary wall. Hydraulic conductivity is a measure of the ease with which water flows through a 
micro-vessel wall (62). The fluid exchange across micro-vessels is driven by the plasma protein 
concentration gradient between the lumen and the tissues. The Starling Principle, which was 
challenged in 1996 and subsequently Michel & Weinbaum et al. proposed that the osmotic barrier was 
not represented by the whole capillary wall, but in fact the endothelial glycocalyx which acts as a 
sieve for molecular proteins (61).  
The past ten years of research in this field have revealed the important role the EGL plays in this 
interaction and its function as a primary mechanotransducer to FSS, its interactions with white blood 
cells (WBC) and red blood cells (RBC) as well as its response to physical disruption have been 
described (61).  
Nieuwdorp et al. showed that loss of the glycocalyx coincides with acute hyperglycemia in patients 
with diabetes mellitus, who already have a propensity for increased vascular episodes (21). The 
resulting disturbance of flow is accompanied by activation of the coagulation system leading to a 
build-up of thrombosis. In their experiments, hyperglycemic clamping resulted in reduction of 
glycocalyx volume and increased plasma levels of 
glycocalyx components such as HA. With the 
addition of N-acytylcysteine (NAC), an anti-
oxidant, the disruption of the glycocalyx could be 
prevented. This suggests that ROS contributes to 
glycocalyx damage in the presence of excess 
blood sugar. Nieuwdorp also suggested that HS is 
vital to NO signaling and the decrease of HS 
resulted in loss of the EC super oxide dismutase 
(SOD) enzyme that catalyses ROS to oxygen, 
noting the important role of the EGL in removing 
free radicals from the blood stream. Perrin et al. 
Figure 11 Stimulation of SMC with PDGF induces 











did an extensive study in 2007 on the effect of excess glucose on hydraulic conductivity and the 
reflection coefficient as well as on compliance. They conclude that the increase in blood glucose alone 
caused an increased micro-vessel permeability in the rat and frog and suggest that understanding the 
mechanisms of this micro-vascular permeability to water may be a target for therapeutic intervention 
in diabetic vascular disease (62). 
The proliferation of cells within the intimal area comprises a collection of SMC, fibroblasts, 
myofibroblasts as well as collagen and PG, together with cytokines, immunoglobulins and other 
factors.  
Endothelial injury is implicated in every aspect of atherosclerosis. It is involved in vasoconstriction 
and vasodilatation, controlling blood pressure, thrombosis and fibrinolysis with secretion of Von 
Willebrand Factor (VWF), NO, thrombomodulin and prostacyclin, inflammation and edema, in its 
production of IL-1, IL-6 and IL-8. The endothelium also produces basic fibroblast growth factor 
(BFGF) and FGF as well as PG, HS, CS and DS. It is involved in filtering functions such as the 
blood/brain barrier and controls transit of white WBC in and out of the bloodstream (61). 
Loss of the endothelium is the hallmark of vascular disease, while damage to the endothelium, results 
in platelet accumulation, and fibrin deposition, leading also eventually to the development of IH. PG 
have been implicated in the formation of IH (53, 55, 63), as well as in association with atherosclerosis 
and the formation of plaque build-up within the artery (61, 64). Perlecan, is an especially important 
EC derived regulator of vascular homeostasis. It has been found to be a regulator of NIH and 
thrombosis and critical for vascular repair, following vascular intervention (53). HA and versican play 
an important role following balloon injury, as they are present in increased amounts in the vascular 
wall, surrounding the proliferating SMC. Evanko et al. showed that stimulation of SMC with PDGF 
resulted in an increase in the pericelluar matrix particularly HA and versican (3) (Fig-11).  
Fischer & Wight et al. showed that the administration of bovine decorin at the site of balloon injury 
reduced SMC proliferation with the use of cell mediated gene transfer. Results showed a 35% 
reduction of NIH over 4 weeks, following cell-mediated transfer of bovine decorin, compared to 
untreated balloon injured tissue. They conclude that over expression of decorin to the injured area 
causes reduced ECM volume and changes to ECM composition (63). Nigro et al. found that 
modification of PG by shortening of the length of GAG chains caused less binding to LDL. Few 
studies have investigated the targeting of GAG chain composition through pharmacological drugs, and 
they suggest that this may be a step to decreasing atherosclerosis and CVD in diabetic patients (17). 
EC secrete and synthesize collagen IV and V, PDGF, vascular endothelial growth factor (VEGF), 
inflammatory cytokines together with PG. Research has better elucidated the role of the glycocalyx in 
the build up to atherosclerotic lesions and the effect of flow mediated shear stress on the endothelium, 











Understanding the role of the glycocalyx has been limited due to poor visualization techniques. 
Currently it is only visible histologically through the use of transmission electron microscopy (TEM) 
following perfusion fixation and staining of the vessel wall (67). In-vivo techniques using fluorescent 
tracers have been successful in evaluating the thickness within a vessel though.  
Restenosis can be defined as the re-narrowing of dilated lesions following PCI. This process is 
complex and only partially understood, but is initiated by balloon angioplasty or stent implantation, as 
treatments for CVD. Acute vessel wall injury results in the denudation of the endothelium from the 
intimal surface, followed by platelet adhesion and monocyte recruitment. The first response is of an 
inflammatory nature, followed by the proliferation and migration of SMC into the intimal region (68). 
This IH layer is a major limiting factor of balloon angioplasty and stent deployment. 
PCI by balloon angioplasty, was first introduced in 1977 by Andes Gruntzig, as treatment for 
restenosis in coronary artery disease (69). The limitations of this procedure became clear with a high 
restenosis rate due to elastic recoil and negative remodeling, while intimal thickening occurred 
secondary to smooth muscle cell proliferation and migration (70).  Today, twice the amount of PCI 
procedures are performed compared to coronary bypass surgery. Restenosis occurs in 20-50% of 
patients after balloon angioplasty and in 10-30% of those receiving a stent, but this prevalence is 
increased in patients with diabetes. Drug eluting stents (DES) have exhibited a high potential for 
reducing restenosis, but recently presented with the risk of late thrombosis and a stroke. 
Rabbits, porcine and non-human primate models show a strong inflammatory response, in comparison 
to human studies that show acute, long lasting inflammation of stented arteries especially when medial 
injury or lipid core penetration occurs (71). Renu Virmani et al. confirmed in a review article in 2007 
that in humans, peak neointimal thickness occurs between 6 months to 1 year with 22% regression of 
neointimal growth after a year. Healing after bare metal stent (BMS) placement in the human coronary 
artery take five to six times longer than in porcine or rabbit models. This finding is critical when 
evaluating the healing pattern of DES, while this could be explained by the fact that there is an 
atherosclerotic process presenting in the fifth to sixth decade of life, compared to research carried out 
on younger, adult animals where stents are placed into normal arteries without an existing 
inflammatory process (42). The molecular mechanisms and patho-physiology of restenosis is 
incompletely understood, but extensive research on several animal models continues, in an effort to 
establish safety and efficacy of vascular devices and therapeutic pharmacology. Despite their 
limitations, animal data goes a long way to developing a better understanding of the complex 












The use of PCI has provided a feasible alternative to CABG for the treatment of coronary artery 
disease, however the need for reintervention due to restenosis remains (72). A multifaceted approach 
to the treatment of CVD and restenosis is necessary. 
Table 5 Possibilities for the development of therapeutic drug prevention. Research for most of these 
conditions is performed in animal models. 
 
1.3.1 Percutaneous Coronary Intervention (PCI) 
The procedure for dilating narrowed coronary arteries is 
known as coronary angioplasty or PCI. This is carried 
out by a cardiologist, and has revolutionized the method 
of treatment for coronary stenosis, previously requiring 
open chest coronary artery bypass graft (CABG). 
Angioplasty is facilitated by injection of a radio-opaque 
contrast agent, during X-ray, to visualize the stenosed 
area throughout the procedure.  
Balloon angioplasty involves positioning of balloon 
catheter into the coronary artery via the femoral artery 
through an incision in the groin. It is positioned before 
being fully expanded with water pressure, followed by 
deflation of the balloon and withdrawal of the catheter.  
1.3.2Coronary Artery Bypass Grafting (CABG) 
The surgical procedure of CABG involves open-heart surgery with or without extracorporeal 
circulation to allow work on the non-beating heart (Fig-12). Diseased coronary arteries are bypassed 
with veins or arteries from elsewhere in the body, which are sutured into position. In some instances, 




Clinical Condition Treatment 
Hypertension, Hypercholesterolemia, Obesity Statins and Fibrates 
SMC proliferation and development of IH Anti-proliferative drugs 
Thrombus formation Anti-coagulative drugs 













1.3.3 Statins  
Statins are LDL lowering drugs. They also have a vascular protective role due to their ability to 
decrease oxidative stress. They reduce proliferation and migration of SMC and also lower plasma 
cholesterol levels. Together with a decrease in oxidative stress, there is an increase in NO availability 
and therefore improvement in endothelial function (16). In support of this, Schaefer et al. described a 
study in which statins block EC proliferation due to hypoxia by preventing ROS and calcium 
formation in response to oxidative stress (73). 
1.3.4 Fibrates  
Peroxisome proliferators activated receptor (PPAR-y) agonists, like Fenofibrate, bind to a family of 
nuclear receptor comprising three sub-types, α, δ and γ. Fibrates are primarily involved in lipid 
metabolism but also have many effects on the vasculature. PPAR agonists are expressed in all the 
major cells in the vessel wall, EC, SMC, and macrophages. They are known to reduce LDL and TG, 
increase HDL and VLDL, as well as have beneficial effects on insulin resistance (39). PPAR-γ appears 
to be the “good guy” in the vessel wall, as it is known to reduce inflammation (74). They are also able 
to detect fatty acids and mediate glucose and lipid metabolism thereby making them ideal treatments 
for MS and DM (75). 
The FIELD study (Fenofibrate Intervention & Event Lowering in Diabetes) found a decrease in 
cardiac events but no improvement to individuals who already had atherosclerosis. Zhao et al. showed 
that the anti-inflammatory Thiazolidinediones, which bind to PPARs and inhibit TNF-α, IL-6 and IL-
1, as well as reduce blood glucose levels, are mediated through nuclear kappa B (NF-k
Dietary supplementation with fish oils, which are natural agonists of PPAR, has been shown to be 
beneficial in the rat model by restoring adiponectin levels and PPAR-α expression in the liver and 
visceral fat. (78). 
ß) pathways 
(76). The effects of PPAR-α and γ were tested by Desouza et al. and found that PPAR-γ reduced IH in 
rats, but not PPAR-α (77). 
1.3.5 Drug Elutin gStents 
The use of DES, affords us a combination of mechanical and biological strategies to combat the 
effects of angioplasty or vascular stenting procedures.  The most commonly used anti-mitotic drugs 
for stent-coatings, include Sirolimus (also known as Rapamycin) and Paclitaxel.  
Rapamycin is an antibiotic as well as a natural fungal fermentation product from Streptomyces 
hygroscopicus, originally found on Easter Island (Rapa Nui Island). It has potent anti-inflammatory 
and immunosuppressant properties. The RAVEL and SIRIUS trials confirmed the reduction of IH in 
humans using sirolimus-eluting stents (79). Paclitaxel is an anti-neoplastic agent, commonly used for 
anti cancer treatment. Kolodgie et al. showed inhibition of proliferation and migration of cultured 











trials to establish these drugs as pharmacological treatments and which have received approval. DES 
were initially considered the answer to restenosis, however thrombosis related cardiac events have led 
to controversial opinions relating to the benefit of DES over BMS (81). Long-term follow-up of DES 
and BMS interestingly show no difference in mortality rate (82). 
More recently coating of stents with glycocalyx components has been introduced. Synthetic 
glycocalyx is covalently bonded onto the stent surface, which promotes the healing process through its 
biocompatible, anti-thrombogenic nature. These stents are made in Germany by Eucatech, and have 
highly polished metal surfaces. They are registered under the trade name “Camoflage”, and the 
coating is composed of N-and O-desulfated, N-reacetyl, which is a modified heparin. This coating 
prevents platelet deposition on the inner-stent surface and reduces the release of growth factors and 
cytokines in the injured area (83).  
1.3.6 Brachytherapy 
Brachytherapy is a form of radiation using a radioactive source, which is placed close to the target 
area. It is currently one of the most successful forms of treatment for restenosis, but not the most 
economical. It has been shown to decrease angiographic and clinical restenosis in new disease and in 
stent restenosis (ISR). The SCRIPPS study (Schripps Coronary Radiation to Inhibit Proliferation Post 
Stenting), showed encouraging results of intravascular radiation for treatment of restenosis. This has 
been confirmed by the WRIST study (Washington Radiation for IN Stent Restenosis Trial), as well as 
by the ARTISTIC (Angiorad Radiation Technology for In Stent Restenosis Trial in Native 
Coronaries). Overall it has been shown that there is a 10% decrease in restenosis with the use of 
brachytherapy (81)  
1.3.7 High Speed Rotational Atherectomy (rotablation) 
Mechanical debulking or rotablation prior to PCI should minimize IH compared with percutaneous 
translumenal coronary angioplasty (PTCI) alone, however these results are debatable. 
1.3.8 Incretins 
Incretins are gut hormones that control insulin release after meals even prior to blood glucose 
elevation, for example Glucagon-like peptide (GLP-1). Exenatide is an example of a synthetic 
analogue to GLP-1, known as an incretin mimic. GLP-1 can be inactivated by agonists like the 
enzyme Dipeptydal pepsidase (DDP-4), however not much is known regarding the effect of either 
DDP-4 inhibitors or incretin mimics on IH following PCI. Diabetic patients on exenatide show 













The following hypotheses are proposed: 
• The effect of obesity has a significant impact on the pathology in the neointima, more specifically 
to the development of IH following balloon angioplasty and vascular stenting in lean, obese and 
pre-diabetic rats. 
• The pro-inflammatory nature of obesity results in an increased inflammatory response and this 
may contribute to increased stenosis following PCI. 
• The impact of vascular stenting has the potential for decreased IH and that the inflammatory 
response to injury together with the response to foreign material within the vessel, may increase 














Intimal Hyperplasia in Animal Models 
2.1 Histological Variations of Vascular Arteries in Different 
Species 
Animal models have been successfully used for the investigation into the effects of balloon 
angioplasty and stenting, primarily rodent, porcine, canine and primate models (71, 84-90). 
These studies have proved invaluable to understanding the mechanisms and pathology of artery 
disease and restenosis. There is, however, a wide diversity of pathophysiology observed in the various 
animal models used in the investigation of type II diabetes, as well as in their individual 
histopathology. 
Rabbit models though have frequently been used for understanding restenosis therapies and show 
stenosis similar to that of humans. Anti-platelet drugs were also shown to reduce IH in this model 
(87). 
 Bergman et al. (90) performed a canine study in 2007, describing the role of obesity in cardiovascular 
risk and in the pathophysiology of MS. Their results support the idea that FFA in visceral fat enters the 
liver where they have detrimental effects on insulin resistance. They suggested that excess FFA are 
released due to SNS hyperactivity in obesity, together with the compounding effects of insulin 
resistance and hypertension, also associated with obesity. The fact that dogs have a significantly 
different coagulation system from humans together with the fact that they produce a very thin 
neoinitma, however, makes them a poor model for restenosis (71). 
The mouse model is not necessarily a practical one due to the size of the animal, wound healing has 
been shown to be similar to that of other models, allowing us a better understanding of SMC 
proliferation and migration and vascular remodeling. The availability of transgenic and knockout 
mouse strains also hold much promise in elucidating molecular mechanisms associated with the 
hyperplastic response as well as in determining the contributions of the immune and inflammatory 
host response.  
Pasa et al. conducted a study on porcine carotid arteries, due to the fact that porcine arteries are similar 
in size and anatomical structure as those of humans. They also noted that pigs raised in pastures 
developed atherosclerotic lesions only after 4-8 years in comparison to those fed on cholesterol rich 
diets, where the changes were seen to be more rapid. In their evaluation of stented and non-stented 
(balloon injury only) arteries, they demonstrated significant IH in the latter, suggesting that balloon 
injury alone was capable of exerting sufficient damage to stimulate intimal cell proliferation (88). 
Spurlock et al. similarly found the pig to be an exceptional restenosis model, with particular regard to 
the involvement of adipose tissue and adipokines in obesity and MS (85). The porcine model also 











days after injury. The degree of IH in the porcine model has also been shown to be proportional to the 
extent of medial damage and IEL rupture (87).  
In the 1960’s the rat carotid artery was established as model for the study of balloon angioplasty, and 
has laid the foundations for an understanding of vascular biology (87, 91, 92). The Zucker rat has been 
previously described as the ideal model for the study of the effects of balloon angioplasty and stenting 
using the carotid artery (93-95). 
Finn et al. established the Wistar rat model for the deployment of stents into the carotid artery, which 
was previously thought to be too small, but highlighted the need for validating the findings of this 
model into larger animals and humans (89). 
The rat model nevertheless offers several areas of study including toxicity, as in DES and margin of 
safety (84). Other parameters include histopathology with assessment of inflammation, incomplete 
endothelialization, adverse effects of drug delivery, molecular biology, medial necrosis, intimal fibrin, 
thrombus formation and PG all of which, cannot be determined by IVUS (intravascular 
ultrasonography) in humans (86, 87), but have been reported in other animal models such as canine, 
porcine and non-human primate models (90, 96, 97). 
Table 6 Characteristics of rodent models used for the study of vascular injury (38) 
              
The interpolation of results from animal studies should of course be carefully undertaken. Several 
factors need to be considered, namely the nature and extent of injury, the state of the arteries being 
injured (non-diseased), the healing response and the variations in the pathology as well as mechanisms 
of each animal model, the variations in inflammatory response etc (98). 
Virmani et al. described changes in the vascular healing patterns between human and animal studies, 
and demonstrated that the time course of healing was more prolonged in human clinical studies. In 
addition, long-term data on animal studies is rare, with most implants extending to only 21-28 days. 
Animal studies are nevertheless critical for the understanding of safety factors of PCI devices, and for 











2.2  The Zucker Rat – Model of Choice 
The Zucker rat model is well established as a model for the study of balloon injury and stenting (89, 
99). The strain was developed in the 1980’s at Indiana University. Following incorporation of a colony 
from Eli Lilly, the strain was then licensed to Genetic Models Inc. in 1991. Ten years later they were 
transferred to Charles River Laboratories (100, 101). The obese rat model offers an opportunity for 
improved understanding of the pathophysiology associated with IH and the impact thereon of obesity 
and MS.  
The rat circulatory system is almost identical to that of humans (Fig-14), but there is substantial 
variation between data obtained from different species and direct extrapolation of findings into 
therapeutic options for patients must be done with caution. 
The Zucker rat has the advantage of three separate phenotypes, allowing for the determination of the 
neointimal response to balloon angioplasty relative to obesity and diabetes as risk factors (Fig 13). 
The Zucker diabetic fat (ZDF) rat is a useful model for the study of type II diabetes, with the male rat 
often becoming spontaneously hyperglycemic, and the female while fed on a recommended high fat 
diet (Purina 5008) (100, 101). ZDF rats display progressive glucose intolerance and hyperinsulinemia 
and like humans, also develop hyperglycemia, hyperlipidemia, nephropathy, impaired wound healing 
and cardiovascular disorders (102). The female Zucker rat is hyperinsulinemic, insulin resistant, 
normoglycemic and non-diabetic, but when fed on a high fat diet, Purina (C13004) containing high 
levels of pork fat) converts to a state of frank diabetes. The lean Zucker rat (ZFR-L) has normal 
metabolic parameters and serves as a useful control (91). A significant difference between male and 
female ZDF rats is that females become glucose intolerant after a longer period of time, and this can 
be useful when testing drugs that depend on the ability to produce insulin (100, 101) 
In contrast to human arteries, there is no vasa vasorum in the rat carotid and it contains a substantially 
thinner sub-intimal layer with less elastin content (103). The homozygous Zucker rat has a deficient 
leptin receptor in the brain, preventing post-prandial satiety. The mutation of the leptin receptor is 
frequently referred to as [Leprfa (fa)]. The homozygous form of the Zucker fatty rat (ZFR-F) Leprfa (fa) 
results in hyperphagia, leading to morbid obesity and IR. Leptin is a small molecule that binds to 
receptors in the hypothalamus, signaling a feeling of satiety. In addition, the Zucker rat has an 
impaired mechanism of insulin release in response to glucose, resulting in hyperinsulinemia. (104)The 


































2.2.1 Anatomical Comparisons of Carotid Ateries of different species 
The structure of arteries varies significantly in their morphological composition and more notably their 
elastin content both within a species and from one species to another. Response to injury, as studied in 
many models also varies considerably. In a comparison by Frank Sims (18) in 1989, the intima of 
human arteries was seen to differ from those of animal models, since they developed intimal 
thickening from a young age. Human coronary arteries with substantial intimal thickening had an 
incomplete endothelium, whereas animal models showed EC closely associated with the IEL. In 
contrast to human arteries, the IEL of animal vessels was observed to be capable of repair.  
In a study by Gabeler et al. the response to injury in three different rat arteries, namely the common 
carotid artery (CCA), the iliac artery (CIA) and the abdominal aorta (AA) were compared. Results 
showed that the decrease in lumen diameter was 
higher in the CCA and CIA compared to that of 
the AA. Possible explanations for this are the 
healing response of different arteries, the elastic 
composition, the vessel diameter and the absence 
of a vasa vasorum in the tunica adventitia of CCA 
(103). Porcine, rabbit and human arteries all have 
vasa vasorum in the tunica adventitia, and Gabeler 
et al. suggest that the CIA and AA in the rat 
perhaps more closely represent the response in 
larger animal models than does the CCA.  
To compare the physiological differences between various arteries, we excised and analyzed the 
histology of the carotid, femoral, axillary and mammary arteries of a Zucker rat  
2.2.2 Materials And Methods 
For the analysis of arterial structure, a ZFR-L rat was anaesthetized with ketamine/xylazine and 
perfusion fixed using 4% PFA in phosphate buffered saline (PBS) following an antegrade heparin PBS 
pre-flush. The four arteries to be studied were located using a stereomicroscope (Nikon-SMZ 800) and 
excised and stored in 4% PFA overnight at room temperature. Existing baboon and procine artery 
control samples were used as comparisons. Samples were dehydrated through graded alcohol solutions 
into xylene and paraffin wax using a Tissue-Tek II tissue processor (see Appendix for methodology). 
Standard embedding procedures were used, except that, due to the length of the samples, a deeper 
embedding cassette was required (Fig 16). This was hand made in our laboratory from Aluminum, 
making it possible to embed a section of approximately 20mm long in one block.  
Sections (3µm) were cut on a rotary microtome (Microm HM 360) and mounted on slides and stained. 
To assess the physiological consistency through the length of the vessel, sections were taken at 280µm 
Figure 16 The modified, deeper embedding 
cassette used for embedding longer arteries and 











intervals and stained with an Elastic Masons trichrome to differentiate between collagen, muscle fibres 
and elastin (Appendix-A-5). The Zucker rat common CCA, axillary, mammary, and femoral arteries 
were analyzed. In addition stock porcine and baboon coronary and carotid arteries, were analyzed, for 
comparison of morphological structures.  
Images were captured on a Nikon 90i microscope. In order to view the complete cross-section of a 
vessel in a single frame, images taken at 10x magnification were automatically aligned and tiled into 
one single composite image. These images were analyzed to compare differences in morphology 
between the various arteries, as well as between different species. 
2.3 Results  
There was considerable variation between the species studied. The most characteristic differences of 
these various arteries was their elastin content as well as the extent of the medial/muscular layer, 
which varied not only within the rat but from one species to another.   
The rat carotid has 3-5 solid bands of elastin interrupted by layers of smooth muscle cells. The baboon 
carotid presented with several finer layers of elastin in a significantly thicker arterial wall, while the 
porcine carotid artery was seen to have a dense muscular wall containing fine strands of elastin at 
irregular intervals and a solid, undulated internal elastic lamina (Fig 17). 
The mammary and axillary arteries of the Zucker rat had a similar morphology with a dense internal 
elastic lamina and a deep band of SMC with intermittent elastic layers surrounded by a collagen-rich 
ECM (Fig 18). 
The femoral artery resembled the carotid artery, with a thinner wall containing 3-4 thick elastin bands 



















Figure 17 Morphological variations between (A) porcine, (B) baboon and (C) rat carotid arteries, together 
with high magnification images D, E and F, stained with elastic Masson’s trichrome 
 
 
Figure 18 Morphological variations between rat mammary, rat axillary and rat femoral arteries, stained with 














It has been suggested that the well-formed IEL, closely associated to EC found in the human 
mammary artery, is not susceptible to intimal thickening or atherosclerosis (18). Sims suggested that 
this combination of IEL closely linked to EC forms a barrier or anchorage onto which endothelial cells 
can attach themselves. Coronary artery thickening which occurs in humans from a young age, most 
likely is not found in non-human primates due to the ‘near perfect’ arrangement of well-formed IEL in 
close contact with EC. The authors concluded that arterial wall structure in different species might 
account for the variations in coronary artery disease that is observed between humans and animal 
models.  This is reinforced by the higher success rates seen with mammary (internal thoracic) arteries 
used as vein grafts compared to SV, both with regard to patency (80-90%) and neointimal formation 
(105). 
The rat model offers a fair degree of IH in response to balloon injury as well as stenting, however it is 
not the most suitable model of inflammation, with maximal macrophage staining being seen at around 
7 days. It does offer the evaluation of the temporal response to small vessel injury with particular 
regard to IH, SMC proliferation and migration, and formation of ECM components. The Wistar rat 
model, was established by Aloke Finn et al. in 2002 as a novel model for carotid artery stenting, and 
had a very similar time course of healing after stent deployment to that of porcine coronary and rabbit 
iliac arteries in spite of differences in elastic and muscular arteries as well as vessel size (89). 
Si Hoon Park et al. conducted a balloon injury study on Zucker male rats in comparison with 
streptozotocin-induced diabetes in Sprague-Dawley rats, and found the Zucker model to be an 
appropriate insulin resistant model with a propensity for NIH (94). 
While porcine and non-human primate models are the closest to human morphology, they are more 
difficult to handle and expensive to work with and not always available. These models do not offer the 
option of acquired or heritable metabolic disorders, such as DM and systemic hypertension. In contrast 
the rat provided a model of obese and/or diabetic with the advantage of being relatively inexpensive. 
Based on these findings the Zucker rat was selected for this study of the effects of obesity and IR on 
















3.1 ZFR-F (Fat) vs ZFR-L (Lean) vs Pre-Diabetic (ZDF) Zucker 
rats. 
In order to evaluate the potential role of metabolic syndrome in the pathology associated with balloon 
angioplasty, the Zucker Fatty Rat (ZFR) and Zucker Fatty Diabetic Rat (ZDF) carotid artery balloon 
injury models were selected specifically to distinguish the risk associated with both an obese and 
insulin resistant state.  
In addition to balloon angioplasty, a further objective of this study was to carry out stent deployment, 
according to the method of Aloke Finn (89). The first stent implants in rat carotid arteries were 
originally done in 2000 by Ciro Indolfi (106). Our preliminary stent work in setting up the model is 
shown in the next section, to compliment this parallel study involving balloon angioplasty and stent 
deployment in Zucker rats 
3.1.1 Materials & Methods  
The institutional animal care and use committee of the University of Cape Town approved all the 
procedures used in this study. Three distinct phenotypes of both male and female Zucker rats were 
used in this study for balloon angioplasty, ZFR-Lean (ZFR–L n=9), ZFR-Fat (ZFR–F n=8) and ZDF 
Fat (ZDF n=9). Rats were kept at 21-23°C, with a 12 hr day-night cycle, and were allowed water and 
standard rat chow, Ad libitum.  
The rats were anaesthetized with ketamine/xylazine (200µl/400g; ratio 9:5ml; i.p.). Buprenorphine 
(0.05mg i.m.) was administered pre-operatively for prophylactic analgesia. Surgery was performed 
aseptically with the use of a Nikon-SMZ800 stereomicroscope (Fig-19). 
Access to the carotid artery was gained via a mid-line neck incision. Heparin (100U/Kg) was 
administered into the jugular vein prior to arteriotomy. Following ligation of the distal left external 
carotid artery (ECA) and application of temporary vascular clamps to the left common carotid artery 
(CCA) and the left internal carotid artery (ICA), arteriotomy was performed proximal to the ECA 
ligation. A Fogarty embolectomy balloon catheter (Edwards 2F) was inserted via the arteriotomy and 
introduced into the CCA target area, inflated to 2 bars (atm) and withdrawn to a point proximal to the 
carotid bifurcation. This procedure was repeated a further 2 times. The effect was to both potentially 
cause endothelial denudation and damage to the elastic lamellae. Following final withdrawal of the 
catheter, air in the CCA was expelled with blood by brief release of the CCA vascular clamp and the 
ECA proximal to the arteriotomy was finally permanently ligated. Blood flow was restored via the 
ICA by removal of both the CCA and ICA vascular clamps, and the incision was closed once 











3.1.2 Follow up 
The rats were observed post-surgery for any complications. Body weight, food intake and blood 
glucose (in the case of the ZDF rats) were tested during a twenty-one day follow-up period. Post-
surgical complications included transient Horner’s Syndrome, most likely due to tissue swelling 
surrounding the sympathetic nerves. This caused ptosis of the eyelid (107). The surgical method was 
refined to further minimize trauma to the nerve tissue overlying the vessels in the operative site to 
avoid this complication.  
3.1.3 Explant Procedure 
Twenty-one days after balloon injury, the rats were anaesthetized as described before and the thoracic 
cavity exposed via a laparotomy extending through the diaphragm. A cannula was placed into the left 
ventricle and phosphate buffered saline (PBS, pH 7.4 containing heparin) was infused using a 
peristaltic pump. This was followed by infusion of Para formaldehyde (PFA; 4% w:v). The left and 
right CCA were finally dissected free, together with the aortic arch and immersed in PFA for 24 hrs 
(Fig-19). The right CCA served as a non-injured control. Macro photographs were taken, using a 
Leica-stereo microscope (MZ75) and Leica (DFC 280) camera. 
 
Figure 19 Explanted Left and Right CCA attached to Aortic Arch. The injured CCA is marked with a stitch. 
(Magnification 0.6 x3 and 1.0 x respectively). 
3.2 Histology and Morphometric Analysis     
The samples were processed overnight in a Shandon Tissue-Tek II processor, containing graded 
alcohol (70%, 90%, 100%), Xylene-100% and paraffin wax. The following day the samples were 
embedded in an upright position into a purpose made deep embedding tray. They were serially 
sectioned using a rotary microtome (Micron H360) from the bifurcation towards the aortic arch to 
evaluate the extent of intimal thickening. Five to ten sections were taken from a point where IH was 
visible and thereafter every 500µm (defined as a level), until there was no further evidence of 
hyperplasia. Each level was labeled accordingly and stored in slide boxes.  
Once the levels were prepared for each explant, one slide from each level was stained with an Elastic 











(Appendix-A5). This stain allows easy visualization of the IH region and allows assessment of the 
extent of elastic lamellae damage.  
Stains were imaged using an automatic stage, at 10x 
magnification, on a light microscope (90i, Nikon) that 
allowed capture of the entire cross-section of the vessel into 
a single tiled image using Eclipse Net software (Laboratory 
Imaging, Prague, Czech Republic). Calibration grid images 
taken at 10x magnification were used to calibrate the image 
analysis (IA) software. IA was performed using Adobe 
Photoshop version 7.0 (San Jose, CA) and IPTK version 5 
plug-ins (Reindeer Graphics, Asheville, NC). 
The extent of the areas inscribed by the lumen and internal 
and external elastic lamellae were defined and measured 
(Fig-19). From this data, the areas occupied by intima and 
media could be calculated. Equivalent thicknesses of lumen, 
intima and media were derived based on approximation of 
the areas to geometric circles: 

















where A = area inscribed by the lumen surface, IEL and EEL. 











The Intima to Media ratio was calculated as follows: 
 
I : M = dIntima
dMedia
 
Within each animal, the mean for each parameter was obtained by selecting the level with maximal IH 
thickness, as well as its four adjacent levels. These levels were then used to report all other 
parameters. 
3.2.1 Statistical Analysis 
 All data was expressed as means ± standard deviation. Inferential statistical analysis involved one-
way analysis of variance testing with post-hoc Student’s t-test (JMP version 6.02 software, SAS, Cary, 
Figure 20 Lines representing the 
lumenal, IEL and EEL diameters, as 
well as IH, Media and Adventitial zones, 











NC). A significance level of less than 0.05 (two-tailed, unless otherwise stipulated) was accepted as 
confirmation of statistical significance following Bonferoni correction for multiple comparisons (Fig 
20 & 21). 
 
Figure 21 Box and whisker plot definitions used in figure 5 
3.3 Results 
3.3.1 Morphomtric Analysis 
ZFR-F rats demonstrated extensive IH compared to the ZFR-L control group. The ZDF group 
exhibited a markedly reduced intimal area (Fig-22). The ZFR-F group exhibited a significantly thicker 
intima compared to both the ZFR-L and ZDF groups (108.2 ± 25.7µm, 71.6µm ± 28.0, 36.4µm ± 21.2 
for ZFR-F, ZFR-L and ZDF respectively; p<0.0001). Both mean stenosis  (45.5% ± 9.1, 30.3% ± 10.7 
and 16.8% ± 9.9 for ZFR-F, ZFR-L and ZDF respectively; p <0.0001) and intima:media ratio (1.42 ± 
0.34, 1.01 ± 0.31 and 0.46 ± 0.26 for ZFR-F, ZFR-L and ZDF respectively; p<0.0001) were similarly 
higher in the ZFR-F and least in the ZDF group. The thickness of the media was not significantly 
distinct between the three groups (60.5µm ± 18.3, 59.0µm ± 8.2 and 69.1µm ± 10.3 for ZFR-F, ZFR-L 
and ZDF respectively; p = 0.23). (Fig-23).  
 
Figure 22 Elastic Masson’s trichrome staining of carotid cross sections (3µm) 21 days post injury, 
demonstrating the elastic lamellae in black and the IH within the IEL, in (A) ZFR-L (B) ZFR-F, and  (C) 













Figure 23 The intimal and medial equivalent thicknesses, intma/medial ratio and % stenosis . 
** Indicates the significantly increased intimal thickness in the ZFR-F group (p<0.0001) 
* Indicates a significant difference in stenosis specifically in the ZFR-F group (p<0.0001) 
3.4 Inflammation 
Obesity predisposes a patient to a pro-inflammatory state concomitant with elevated CRP and cytokine 
levels (108) and an increase in a risk for CVD. Excess adipose tissue translates into inflammatory 
mediator levels, which contributes to the underlying inflammation. Significant weight loss has resulted 
in decrease in CRP, IL-6 and IL-18 levels and raised adiponectin levels. This in turn serves to mitigate 
an otherwise pro-inflammatory state. Strong evidence suggests that inflammation correlates with the 
degree of injury, which varies depending on whether that injury is a result of balloon angioplasty or 
stent deployment (109, 110). An increase in plasma CRP levels is known to promote both 











Elevated CRP plasma levels are also noted in diabetes. Increased CRP is also a common histological 
finding in atherosclerosis (98) and is associated with components of MS, such as hyperglycemia, 
hypertension, obesity, decreased HDL.  
It was therefore important in this study to evaluate the inflammatory status by histological analysis of 
selected contributors to this process, namely CRP, macrophages, IL-6, adiponectin and immune 
complexes IgG and IgA.  
3.4.1 Materials and Methods  
 
3.4.2 Specific Markers 
The following six markers were set up to assess the level of inflammation, and set up as follows:  
• Polyclonal C-Reactive Protein (CRP) rabbit anti rat (Abcam: ab 47795) 
• Polyclonal Rabbit anti rat IgG/ FITC Conjugated (Serotec: Star 17B). 
• Polyclonal Goat anti rabbit IgA (Komabiotech: K0211684). 
• Monoclonal mouse anti rat macrophage marker CD 68 (Clone ED-1) (Serotec: MCA341R). 
• Polyclonal rabbit anti rat Adiponectin (Abcam: ab3455). 
• Polyconal Goat anti rat IL-6 (Cedarlane: CL9571AP) 
3.4.3 Immuno-Fluorescent Staining  
All antibodies were diluted in 1% bovine serum albumin (BSA) in PBS to minimize background 
staining. The levels selected were with maximal IH from each rat explant, usually occurring at the mid 
point of the injured area. Since these were wax embedded tissues, serial sections, 500µm apart from 
each level were sectioned and stored for future use. Each slide included the corresponding, un-injured 
control artery from the same rat, which served as a control. The sections were de-waxed in xylene, and 
brought to water through graded alcohol. Antigen retrieval, using P XIV (Sigma) or proteinase K 
(Diagnostech) pre-treatment, to break down covalent bonds induced by formalin fixation, was 
performed where necessary depending on the primary antibody used. Standard immunohistochemistry 
for paraffin embedded tissue was done using appropriate primary antibody dilutions in 1% BSA 
(Appendix A -7). The appropriate anti-mouse or anti-rabbit fluorescent secondary antibodies were 
applied and incubated in the dark (Donkey anti-mouse for monoclonal; and Donkey anti-rabbit/goat 
for polyclonal antibodies). All slides were mounted in DAPI nuclear mountant (Vector shield) to 
differentiate the nucleus, and protected from light to preserve fluorescence (Appendix-A7.1). Images 
were taken immediately, to prevent photo bleaching of the fluorescent signal, using a fluorescent 
microscope (Nikon 90i). Appropriate filters for the various fluorochromes were selected (e.g. Alexa 











A scoring system was used to assess the level of positive staining, individually for the intima, media 
and adventitial zones. Scores of +, ++ and +++ were arbitrarily defined for ED-1, CRP, IgG and IgA 
antibodies, negative controls were set up to ensure that positive staining was not due to non-specific 
antibody binding. This step involved sections without the addition of a primary antibody, but 
undergoing all the steps that the test slides went through, to rule out the possibility of secondary 
antibodies binding to immunoglobulins in the tissue. 
 
3.4.4 Results 
Very few macrophages stained positively within the intimal or medial areas in any of the three groups 
based on the monoclonal antibody (ED-1 Serotec-CD 68). Occasional macrophages were observed in 
the intimal zone and within the media but, more frequently, they were seen in the surrounding 
adventitial zone (Fig-23).  
IgG staining was largely absent in the intima of the diabetic group but strongly positive in the 
adventitia (p=0.025). In the ZFR-F and ZFR-L groups however, there was no statistically significant 
difference between the layers (N.S) (Fig-24). The intima, media and adventitia of the ZFR-F group 
displayed staining for IgG but this was no different from the ZFR-L group (Fig-25). Mild staining for 
IgA was found in the intima, media and adventitia of the obese and lean group, with strong staining in 
association with the endothelial cells in the ZFR-F group (Fig-26). The diabetic group showed 
substantially reduced staining in comparison to the fat and lean, with no evidence of endothelial 
association, in spite of confirmation of the presence of an endothelial layer by VWF immunostaining. 
(Not shown ). 
C-Reactive protein showed variable staining within each group, but most notably it was intensely 
stained in the intima in all groups (Fig-27). The majority of ZFR-L arteries displayed highly variable 
staining in the media, intima and adventitia, varying from severe to nil. The ZFR-F group displayed 
strong CRP staining in the intima only, and the ZDF group only displayed some strong staining in the 
intimal and some medial areas, as can be seen from the charts in (Fig-26). No statistical differences 











Adiponectin staining was 
strongly detected in the intima 
and media of the ZFR-L group, 
compared to the adventitia 
(N.S). The ZFR-F group showed 
a trend towards stronger staining 
in the intima compared to the 
media and adventitia. The ZDF 
group, however, stained strongly 
for adiponectin in all layers but 


















 Figure 24  IgG comparative staining between ZFR-F and ZFR-L 















 Figure 26 IgG, Adiponectin and mosaic plots for adventitial, medial and intimal layers. 
 
Figure 25 F Comparative values of IgG between the anatomical layers 












Figure 27 Immunohistochemical staining of IgG(FITC), IgA(Alexa 488), CRP(Alexa 488) and ED-1(Cy3) at 











3.5 Staining of GAGS (PG) using a Modified-Movat stain 
PG can be detected by individual immunohistochemical staining, but in general by histochemical 
staining using Movat stain. This stain is similar to that of a Masson’s trichrome in being able to 
differentiate muscle, collagen and elastin, but additionally stains PG and GAGS in blue. In general the 
most prevalent PG detected by the Movat is CS. 
3.5.1 Materials & Methods  
Serial sections to area of maximal IH thickness from the balloon injured area were dewaxed through 
xylene and graded alcohol to water, and stained with a modified Movat stain (Appendix A-6). The 
Verhoef’s solution allowed visualization of the elastic fibres (black), with Van Gieson counterstain 
differentiating collagen from muscle. The PG components stained using Alcian Blue (1%). Sections 
were scored according to scoring system described previously  
3.5.2 Results 
The arterial wall of balloon injured carotid arteries consistently demonstrated very limited GAG 
staining as detected by the Movat stain (Fig-29). Occasional clumps of blue PG staining were seen in 
the tunica media and tunica intima, in comparison to the un-injured control vessel that failed to show 
GAG staining. Positive PG staining was best viewed under high magnification, but there were no clear 
differences between the ZFR-F, ZFR-L and ZDF groups. Figure-30(B) shows a baboon coronary 
artery SV graft, 6 months after CABG, and a artery twenty one days post angioplasty rat carotid Fig-
30(A), modified Movat stain. This was to demonstrate the differences in PG content in the two species 
at different time points. It is important to note that Movat staining predominantly identifies the CSPG 
and not HSPG type (112). 
  
 
Figure 28 Numerical scoring of GAGs in anatomical layers in representative examples ZDF, ZFR-F and 
ZFR-L rats. 












       
       Figure 29 Modified Movat staining of a selection of ZFR-F, ZFR-L and ZDF Zucker rats. Images 
       were taken at 10 x magnification. High magnification 20 x demonstrating the GAG components  
       staining with Alcian blue. 
        
  Figure 30 Rat carotid artery 21 days after angioplasty and stented baboon coronary artery 6 months 











3.4 Glycocalyx Analysis 
3.4. Introduction 
The glycocalyx is made up of a network of PG and glycoproteins, predominantly of the HS variety. 
Although Movat staining did not show differences between the rat groups with respect to PG we 
decided to re-examine whether differences did exist with regard to specific PG (i.e. CS and HS) (56). 
The critical role played by the endothelial glycocalyx has been acknowledged in recent years, however 
the challenge to determine if it could be a marker of cardiovascular disease remains. In addition, there 
is a need to assess whether restoring the glycocalyx would have an influence on the process of 
atherosclerosis and, therefore, how therapeutic intervention in this regard could be useful in the 
clinically (113).  
The presence of Heparan Sulfate (HS), as a major component of the glycocalyx and that of the artery 
wall, has been demonstrated in the intima and media of vascular tissue (114). However, the evidence 
of HS, as part of the surface endothelial glycocalyx, using light microscope techniques, has not yet 
been published. All previous detection of the glycocalyx has been demonstrated by electron or 
confocal microscopy (22).  The glycocalyx is destroyed during processing and paraffin embedding.  
The presence of the glycocalyx can be seen in the typical tuft-like formation described in previous 
studies using transition electron microscopy (TEM)(115). 
Three techniques were set up to confirm the presence of the HSPG. Light microscopy 
immunohistochemistry; confocal immuno-fluorescent-histochemistry and TEM incorporating Alcian 
Blue staining.  
3.4.2 Materials & Methods  
3.4.2.1 HeparanSulfate (HSPG) Immunohistochemistry 
The most prevalent PG component of the endothelial glycocalyx is HS and was therefore targeted to 
detect the presence of HS on the luminal surface, in the intimal area and throughout the arterial wall, 
using immunohistochemical techniques. 
3.4.2.1.1 Light Microscopy 
Cross sections of ballooned, right common carotid (RCC) artery at the maximal point of IH, together 
with control, left common carotid (LCC) artery from the same rat, were immunostained for Anti 
Heparan Sulfate (Abcam-ab2501). Sections were dewaxed and taken to water through xylene and 
graded alcohol solutions, as previously described. Blocking for endogenous staining was performed 
using hydrogen peroxide (3%) in methanol to prevent endogenous staining. Antigen retrieval using 
Proteinase-K, to better expose antigen sites obscured through the formation of covalent bonds during 
formalin fixation, was performed for 10 minutes prior to application of goat serum (1:20 in PBS for 20 
minutes), to minimize background staining. Incubation with the primary antibody diluted 1:100 (in 
PBS + 1% BSA) was performed overnight @ 4°C. Sections were washed in tris-buffered saline (TBS), 











Streptavidin-peroxidase (Histomark: 71-00-38). True Blue-HRP (Histomark: 71-00-68) was used as 
the chromogen due to its much higher sensitivity compared to diamonobenzidine (DAB). Colour 
development was maximal after 5 minutes, and sections were counterstained with Neutral Red (0.25% 
for 2 seconds). Slides were air dried and mounted in Entellan (Appendix A-7.2). Negative controls 
excluded primary antibody to rule out non-specific secondary antibody binding. The un-injured left 
carotid vessel also served as a control. 
3.4.2.1.2 Confocal Imaging 
Confocal imaging is a method to visualize cellular components incorporating immunohistochemical 
techniques, in which whole mount samples can be viewed using optical scanning. This method does 
not require tissue fixation and therefore causes less structural damage and dehydration to the tissue by 
solvents and alcohol solutions, resulting in better preservation of the glycocalyx components in the 
lumenal area 
To demonstrate the presence of Factor VIII containing endothelial cells adjacent to HSPG at the EC 
surface, double immuno-fluorescence staining was performed on freshly explanted, un-fixed carotid 
artery. The carotid artery was harvested as previously described but without fixation. The tissue was 
treated with HEPES buffer, before being stained with a cocktail of two antibodies, namely HS 
(ab2501) and von Willebrand factor (VWF- M0616 Diagnostech] (Appendix A-7.3) to allow 
visualization of the endothelium, stained with VWF/Cy 3 (red) and HS stained with Alexa 488 (green) 
on the luminal surface. Visualization was effected on a Zeiss confocal microscope and images 
captured in two separate channels and combined into a Z-stack (See Fig-15). 
3.4.2.1.3 Transmission Electron Microscopy 
Transmission electron microscopy, for very high magnification visualization, was used as a third 
technique, to demonstrate the presence of the endothelial glycocalyx. A special process of fixation and 
staining was performed, according to a protocol obtained from a research group in Maastricht, and 
which utilized Alcian Blue staining. 
Carotid arteries harvested 21 days after balloon injury, were used. The arteries were initially perfused 
for 5 minutes with HEPES buffered salt solution, followed by 30 minute of perfusion with a 
fixative/staining solution containing 1% Alcian Blue and Magnesium Chloride (MgCl2
Samples were dehydrated and embedded in Spurrs resin, and polymerized at 60°C overnight. A Leica-
Ultracut microtome was used to cut thin (100-200nm) sections using a glass knife (Appendix-A-9.11). 
Sections were picked up and placed onto grids for staining and viewing on the electron microscope. A 
) at a flow rate 
of 8ml/min. The Alcian Blue solution required continuous agitation to keep it in solution. Thereafter, 
carotid arteries were explanted according to the procedure previously described and placed in 
McDowell’s fixative overnight. This was followed by post-fixation and en bloc counter staining with 











Phillips EM420 electron microscope was used to visualize sections, and images were captured using 
an AnalySIS program (Appendix A-9.12).  
3.4.3 Results 
Light microscopy demonstrated the presence and extent of the EGL. Both the lean and the fat ZFR 
groups showed variations in HS staining, with several displaying a substantial endothelial glycocalyx. 
The ZDF group showed occasional presence of a glycocalyx, with positive HS staining in the IH 
region as well as patches in the media (Fig-31C). There was no evidence of an endothelial glycocalyx 
in the control vessels, but they had positive staining for HS in the media and/or adventitia (Fig-31B).  
A scoring system was used to quantify the findings. The thickness of glycocalyx was scored from 1-4, 
and the % coverage was estimated (Fig-32).  
 
Figure 31 Heparan Sulfate Immuno-staining of A - Balloon injured right carotid artery showing IH and the 
presence of glycocalyx; B - Control left carotid artery of the same rat, showing no IH or Glycocalyx, but 
positive HS staining in the media; C - High Magnification (x 20) of HS staining of the intma, media and 














Figure 32 Anti-Heparan Sulfate/True Blue Immunostaining of (A) ZFR-L; (B) ZFR-F and (C) ZDF showing 
Glycocalyx, intimal and medial staining of HS. Original magnification 10 x). 
 
  
Figure 33 The glycocalyx thickness score in relation to fat (ZFR-F) vs lean (ZFR-L) on the left, and the 













Figure 34 Confocal Imaging on fresh Carotid Artery double stained with Anti-HS/Alexa 488 and Anti-
VWF/Cy 3. A-C View from above of EC surface; D-F Endothelial Edge; G-I High Magnification of 
Endothelial Edge. 
Confocal imaging showed double staining in spite of high background in the green channel. Results 
indicated the presence of HS on the lumenal surface in green, closely associated with the endothelial 
cells containing VWF, in red (Fig-34). 
Transmission electron microscopy confirmed the presence of a glycocalyx on endothelium of the 
balloon injured carotid artery (Fig 35). Although the structure appeared slightly clumped in 
comparison to published images, this was attributed to the fact that the perfusion pump flow rate was 












Figure 35 TEM on balloon injured carotid artery using Alcian Blue staining to demonstrate the presence of 
glycocalyx on the surface of the endothelium (A, B & C) although this was not consistent in all areas D. 
 
3.5 Pathological Changes 
Morphological changes to peripheral organs, such as the pancreas and the kidney are not uncommon 
in association with DM2. Its association with intimal hyperplasia is less well documented. We 
performed histology on both organs to assess their pathological state and determine if there was any 
correlation with the extent of IH. 
3.5.1 Hydronephrosis  
Pathological changes observed in the kidneys of Zucker rats have been well documented (116-119). 
This phenomenon, first described by Vora et al in 1996, can be detected in obese and diabetic Zucker 
breeds, and to a lesser degree in lean rats. 
3.5.1.1 Materials & Methods  
To ascertain the extent of renal damage in the zucker rat model, the kidneys were excised at explant. 
Left and right kidneys were cut in half and embedded in wax. Comparative histological evaluation was 
conducted on lean, obese and diabetic models, with the damage being scored according to severity. 











the kidney, while macrophage accumulation was determined by ED-1 fluorescent staining. As a 
measure of the extent of interstitial and glomerular fibrosis and an early indicator of nephropathy, 
smooth muscle actin was done by immunofluorescent techniques. 
3.5.1.2 Results 
Severe hydronephrosis is evident in virtually all of the ZFR-F rat kidneys, bilaterally in many cases, 
while three out of ten ZFR-L showed mild hydronephrosis (Fig 36), as stained with Haematoxylin and 
Eosin (Appendix A-4). ZDF showed hydronephrosis in some cases, however many unilaterally, and 
some not at all. This is determined by dilation of the renal pelvis, occasionally presenting as complete 
hollow areas in the medulla, extending to the cortex. The glomeruli of the lean rats appear fairly 
normal with no evidence of glomerulosclerosis. The squamous cells lining the Bowman’s capsule are 
in tact, and there is no tubular dilation in the medulla or cortical region. There was no sign of 
ascending infection, which is a cause of hydronephrosis. There was no correlation of kidney damage 
to changes in IH. 
 
Figure 36 Histological Changes in the Kidneys of Zucker Rats; A - C Hematoxylin & Eosin on ZFR-L, ZFR-
F and ZDF (Magnification 2 x tiled images). D - F Immunofluorescent Staining for IgG/FITC 
(Magnification 20 x). 
3.5.2 Pancreatic Islet Morphological Changes 
In the course of our study, we looked at the morphological changes that occurred in the pancreas 












3.5.2.1 Materials & Methods (Pancreas) 
The pancreas was harvested from ZDF- F, ZDF- L and ZDF - F rats and processed according to 
standard wax embedding procedures. Sections (3µm) were cut on a rotary microtome as previously 
described and stained for Haematoxylin and Eosin (Appendix A-4), modified Masson’s trichrome 
(Appendix-5) and immunohistochemical (Appendix A-7.4) staining of Insulin, to determine 
morphological changes of the islets of Langerhans, beta cells and the surrounding acinar tissue. Image 
analysis data of the islet morphology was compared between the three groups with regard to the size 
of individual islets and the total islet area (JMP version 6.02 software, SAS, Cary, NC). 
Results 
The mean cross sectional area of islets in the ZDF obese rats was markedly higher than either the 
ZFR-F of ZFR-L rats (112493±35013µm2 
Positive immunohistochemical staining for insulin confirmed ongoing production in the beta cells of 
the ZDF group despite the abnormal morphology observed (Fig 37).  
versus 44767±39001; p=0.024 and 23463±894; 
p=0.005respectively; Dunnett’s t-test). The ZFR-L rats exhibited not only smaller, but also rounder, 
more uniform islets with defined boundaries compared to the ZFR-F and ZDF obese rats (Fig-38). 
 
 













Figure 38 Histology of the pancreas: A-C Zucker Lean; D-F Zucker Fat; G-I Zucker Diabetic, stained with a 














The restenosis in arteries following balloon angioplasty remains a major cause for concern. The role of 
obesity and MS in this pathological response, are not fully understood, however the phenomenon is 
believed to be exacerbated by hyperglycemia and IR. Obesity plays a role in the resultant EC 
dysfunction and development of IH and this is aggravated by, but not dependent on, hyperglycemia 
(120). This study of vascular morphology following injury has shed some light on the formation of IH, 
the components thereof within the intima, the effect on the endothelial glycocalyx layer and the effect 
of obesity on vascular pathology that follows.   
The initial surgical intervention, which balloon angioplasty and stenting, represents, in itself elicits a 
response-to-injury, in the form of an inflammatory response and proliferation of SMC to the intimal 
area. The extent of the injury is determined by denudation of the endothelial surface, with or without 
rupture of the internal and even the second or more layers of elastic lamellae in the tunica media. The 
mechanical damage caused by intervention is variable and dependent on pressure applied during 
angioplasty as well as surgical isolation of the artery (in the case of animal models), and the effect of 
moving the balloon backwards and forwards within the vessel. This could be an external factor that 
may be seen as a limitation in the analysis of the response to IH, since the degree of IH is directly 
linked to the degree of endothelial denudation (121). The extent of the development of IH can be seen 
on the histology of the vessel through cross section, with obese animals displaying a greater level of 
IH than the lean controls. The ZDF group had a significantly lower level of IH, against our 
expectations, in spite of being overtly obese, with glucose levels higher than the normal range. This 
finding raises further questions with regard to obesity as a risk factor for IH, since the ZFR-F and ZDF 
groups were both overtly obese, but displayed such contradicting IH values.  
In the stented groups, there was little variation in the degree of IH between all three groups. The pre-
diabetic (ZDF) group displayed less IH than the ZFR-F group, in spite of being overtly obese. The 
mechanism for this is not clearly understood, but was previously documented by Jonas et al (2005) in 
a study on vascular response to stenting. Their finding was that the ZDF group displayed a similar 
degree of IH to that of the ZFR-L control group. Their suggestion is that the reduced IH is due to the 
weight loss incurred by diabetic rats in response to a hyperglycemic state, confirmed by previous 
studies (94, 106) and thereby creating a catabolic state. This highlights the role of hyperinsulinemia 
and IR as opposed to hyperglycemia as the driving force behind increased neointimal response (99). 
This was not confirmed by our study, as our animals were not yet hyperglycemic. 
The presence of a stent significantly reduces the development of IH, within the stent area. Interestingly 
the area immediately beyond the stent showed a greater IH in the fat group, compared to the lean, and 











The majority of cellular material in the IH zone appears to be of ECM (60-80%) and SMC (20%) 
origin. The latter may be of the contractile (actin and myosin positive with a low proliferation rate or 
synthetic (myosin negative with a 10% increase in proliferation rate) phenotype, but producing four to 
five times more ECM deposition than the normal contractile phenotype. In IH there is an increase in 
the synthetic phenotype at the expense of contractile phenotype (122).  
The intimal region of ballooned and stented vessels contained substantial amounts of elastin in this 21 
day period, coinciding with the decreased secretion of PG (40). 
The EC layer and the glycocalyx are critical to the normal functioning of the endothelial surface and 
play a vital role in the development of IH. EC dysfunction through mechanical trauma and a 
compromised glycocalyx affect the events leading to cell proliferation. The presence of endothelium 
was visualized by immunofluorescent VWF staining, and evidence of a glycocalyx was demonstrated 
by light microscopy, confocal and TEM. The discovery of the functions of the EGL in the past decade 
has brought to light the fact that this is a highly active layer constituting modulators in the formation 
of the NIH following vascular injury after PCI. Electron microscopy has been the only method of 
visualization of the glycocalyx since its discovery in 1962 (123). Ruthenium red or Alcian blue were 
used in the staining procedures, which have been refined sufficiently to enable the visualization of the 
glycocalyx. By 1979 the role of the glycocalyx was still unclear until Klitzman and Duling suggested 
that the vascular glycocalyx takes up a large proportion of capillaries causing limited capillary filling 
and low capillary haematocrits (32). In 1996 Vink et al reported that there was a “gap” between 
flowing red cells and the endothelium using intravital microscopy, suggesting that the glycocalyx 
measured approximately 0.4 - 0.5µm in thickness (124). Subsequently, much research has been done 
on the physiological role of the glycocalyx and to establish its thickness. This has been hampered by a 
lack of good visualization techniques. During histological preparation of samples, the glycocalyx is 
vulnerable to structural damage or dehydration, and therefore the method of TEM pre-preparation of 
tissue is critical for successful visualization.  
The study of the EGL has revealed that it is not simply a bystander in the development of IH, as it is 
involved in shear stress changes that act as a mechanotransducer to the vascular wall. It possesses both 
anti-inflammatory and anti-thrombotic effects, it has an influence on the production of elastin, and it 
regulates SMC proliferation, and is known to be compromised in patients with DM2 who are prone to 
increased rates of NIH. The finding that HS stains the glycocalyx of balloon injured arteries could 
suggest that up-regulation of HS that occurs following injury may result in the expression of a much 
broader glycocalyx layer that then becomes detectable by light microscopy. Substantially increased 
glycocalyx on thickened IH may be a protective mechanism to deal with changes in FSS caused by 
luminal narrowing. Importantly, Bakker et al indicates that CSPG are increased in DM2 at the expense 











Hydronephrosis is a pathology that occurs in Zucker obese and pre-diabetic rats but less so in lean 
Zucker rats (117). Morphological changes occurred in the kidneys of ZFR-F and ZDF rats, bilaterally 
in some cases. This was very rarely seen in the ZFR-L rats, and where present, was mild.  
Hydronephrosis is the distention and dilation of the renal pelvis and calyces caused by obstruction of 
the free flow of urine from the kidney. This in turn leads to atrophy of the kidney. Renal complications 
include tubular dilation, necrotizing granulomas, inflammatory changes and pyelonephritis. Their 
findings suggested that the Zucker diabetic fatty rat (ZDF/Drt-fa) rat model closely mimicked the 
metabolic status of humans in NIDDM, and therefore offered a suitable model for research pertaining 
to this disorder (116). In 2007 Marsh et al completed a study on ZFR-F, ZFR-L and ZDF rats with 
relation to cardiovascular dysfunction and found that hydronephrosis was indeed a limiting factor for 
studies on renal or cardiovascular function, since both systolic and diastolic dysfunction was noted. 
Moderate to severe renal dysfunction was observed independently of obesity or diabetes in ZDF and 
ZFR-F rats, compared to mild dysfunction in ZFR-L and Sprague-Dawley rats. The combination of 
hydronephrosis and hyperglycemia, was confirmed as representing an adverse effect with respect to 
cardiac function. The presence of a low angiotensin II level in ZDF rats together with left ventricular 
dysfunction and increased norepinephrine levels, suggests a blunted rennin-angiotensin system (117). 
Chow et al conducted a study on mice in 2004, with regard to macrophage accumulation in the kidney, 
contributing to type II diabetic nephropathy, and concluded that macrophage-mediated injury to the 
kidney was associated with increased chemokine production and glomerular immune complexes 
(119). Nakagawa et al did a study on VEGF in relation to diabetic nephropathy, since decreased 
VEGF levels are associated with renal dysfunction. However in diabetics, renal dysfunction occurred 
in spite of high VEGF levels. The authors suggest that, since the protective role of VEGF could be due 
to it’s ability to produce NO, and since NO is depleted in diabetics, perhaps the uncoupling of VEGF 
with endothelial NO was the mechanism by which VEGF caused diabetic nephropathy (118). A study 
by Erdely in 2004, found that obese hyperglycemic, hyperlipdiaemic zucker rats develop severe 
kidney disease due to a reduction in renal eNOS activity and nNOS protein abundance, which do not 
resemble human diabetic nephropathy (125). 
Two possible methods of improving renal complications include the use of troglitazone, to correct IR 
and PPARy agonists that normalizes plasma glucose (126, 127). Hayashi et al demonstrated that the 
correction of IR with troglitazone restored the vasodilator action in micro vessels of Zucker obese rats, 
and was therefore a useful strategy for prevention of glomerular sclerosis in IR conditions. Baylis et al 
found that PPARy agonist was a potent protective component of chronic renal disease in the Zucker 
rat. Nevertheless, in our study, it did not appear to influence the extent of NIH, and the time-point 
studied here did not allow for catastrophic renal failure to develop. 
The histology of the pancreas confirmed that obesity appears to have a direct effect on beta cell 
dysplasia. This takes place before the onset of hyperglycemia. This finding alone supports the 











disease. Obesity is clearly a risk factor for an enhanced intimal response to injury. This response is 
independent of glycemic levels, since the ZFR obese group was normoglycaemic as was the ZDF 
group. This suggests that hyperglycemia alone was not responsible for IH development.  
The morphological dysplasia shown in the islet histology of the pancreas, indicate that metabolic 
changes or beta cell changes, occur early in the course of DM2 and that these changes are a result of 
abdominal obesity with excess FFA in the circulation which have an impact on IR. Histological 
confirmation of significant islet hyperplasia noted in the obese and diabetic rats, in comparison to the 
lean controls, may suggest that future treatment should be aimed at control of obesity before IR or 
hyperglycemia. Our data confirms the findings of Tokuyama et al in that the ZDF-F group had not yet 
become hyperglycemic, yet already presented with changes in islet morphology.  Islets of diabetic rats 
become hypertophic and dysmorphic with several irregular projections into the surrounding exocrine 
pancreas (24). 
The pancreas of obese and diabetic rats has displayed changes in islet morphology (24, 128, 129). Beta 
cells found within the Islets of Langerhans, make up 65-80% of cells in the islets. These cells produce 
and release the hormone insulin, which controls glucose metabolism. They also secrete C-peptide, 
involved in prevention of neuropathy, as well as amylin for glycemic control. Weir et al proposed that 
there are five stages of beta cell dysfunction with changes in beta cell mass, phenotype and function at 
each stage (130). 
Beta cell dysfunction occurs long before hyperglycemia manifests itself (24) and patients presenting 
with diabetes type II have lost 50% of their beta cell function already (128). Holst et al, in an 
endocrinology review, suggested that incretins might be an exciting future target for treatment of type 
II diabetes. They reported that animal studies which had shown that the incretin (GLP-1) as well as 
inhibitors, DPP-4 (dipeptidylpeptidase) responsible for the degradation of GLP-1, lead to beta cell 
proliferation and cytoprotection. GLP-1 protects the ischemic and re-perfused myocardium in rats by a 
mechanism independent of insulin. GLP-1 is also known to improve endothelial cell dysfunction as 
well as increase left ventricular pressure (129). Inhibition of DDP-4 enzyme,T cell antigen could be a 
potential mechanism for preventing DM2, by enhancing circulatory levels of GLP-1. DPP-4 is 
currently on the market by Merck as Sitagliptin or Novartis as Viblagliptin. Holst conclude that 
incretin based therapy may halt progression of DM through their protective and perhaps trophic effect 
on beta cells (129). 
In a review by Frode on drug testing using animal models with respect to their potential anti-diabetic 
activity, they highlight the importance of controlled food intake in determining the severity of the 
diabetic phenotype on the ability of beta cells to produce sufficient insulin. They also conclude, even 
as recently as 2008, that a standard model of experimental diabetes to study drug efficacy, has yet to 
be established (128). In his review, Frode lists natural products with anti-diabetic properties, and 
stresses the need to focus on other targets of pancreatic islet dysfunction in new models to determine 











A large component of atherosclerosis and the higher post-percutaneous coronary intervention (post-
PCI) risk for restenosis, associated with metabolic syndrome and DM2, involve an inflammatory 
response. This risk often translates into the requirement for vascular intervention or reintervention. 
This commonly involves either balloon angioplasty alone or together with stent deployment. PCI 
involves mechanical injury to the vascular wall in the form of endothelial denudation and disruption of 
the internal elastic lamella, but often extending to the external elastic lamella as well as trauma to the 
smooth muscle cells of the tunica media. This triggers an inflammatory response with migration and 
proliferation of SMC to the intimal area, together with T and B cell recruitment, in the formation of an 
intermediate lesion (93). In the complex inflammatory process following injury there is a release of 
cytokines, adipokines and proteins like adiponectin, MCP-1 and CRP as well as anti-inflammatory 
cytokines like TGF-beta and IL-10, which inhibit T cell mediated immunity (5).  
The state of obesity commonly found in diabetic subjects, contributes to their pro-
inflammatory condition. Adipose tissue is characterized by an abundance of macrophages that are a 
source of adipokines including CRP, IL-6, IL-8 and TNF-alpha (131). Yudkin et al. suggested that 
adipose tissue is associated with a chronic inflammatory state and that this may induce the IR 
and EC dysfunction that is associated with obesity and CVD (132).  
CRP is synthesized in the liver in response to inflammation and adipose cells stimulate its production. 
The elevation of CRP levels, is a predictive marker for heart disease in healthy individuals and has 
been found to be elevated in the presence of obesity (132). The term hs-CRP refers to high sensitivity-
CRP, which is an ultra sensitive laboratory test used for the detection of the protein, CRP. CRP levels 
are increased during systemic inflammation and this is implicated in increased risk of restenosis 
following balloon injury (33).  
The recruitment of macrophages to the site of injury is part of the inflammatory response generated by 
balloon angioplasty. A 2006 study on the chronology of macrophage infiltration post injury, noted that 
macrophages infiltrate the area within 3 days following angioplasty, are still present at 14 days (133). 
Thereafter they begin to decline. Immunoglobulin G is produced by B cells as a secondary antibody 
immune response following activation by pro-inflammatory cytokines notably the interleukins. We 
assessed the degree of immune response following injury, using selected inflammatory markers. At the 
time point defined by our study, there was a distinct absence of inflammatory cells but a significant 
expression of inflammatory mediators such as CRP and IgG. 
The complex mechanism of restenosis has confounded investigators for many years, and clearly 
targeting of individual role players has not achieved the desired mitigation of this process. 
Inflammation is a driving force, however, several other vitally important factors are required to 














Carotid Artery Stenting in ZFR-L, 
 ZFR-F and ZDF Rats. 
The treatment of atherosclerotic lesions, typically involves the use of balloon angioplasty in 
combination with stent deployment to the stenosed area. In order to additionally assess the interaction 
of stenting with the effects of obesity and IR on IH development, we conducted a parallel study on 
three similar groups of rats; ZFR-F, ZFR-L and ZDF by performing angioplasty with the addition of 
stent deployment into the carotid artery.  
4.1 Bare Metal Stents  
Andreas Gruntzig first introduced stent implantation in 1977(69). This was a major breakthrough in 
the treatment of vascular stenosis, replacing coronary bypass surgery. Initial success rates were high, 
but in time, restenosis rates became unacceptably high. Intra-coronary stenting has to some extent 
addressed elastic recoil, but restenosis levels are in the region of 15-30% (81). Risk factors 
contributing to IH in stented arteries include lesion length, cross-section lumen area following 
stenting, atherosclerotic plaque, number & length of stents used, as well as clinical factors such as MS 
and DM2. The process of neointimal formation in stents following arterial injury primarily comprises 
thrombus formation, leukocyte activation and migration, SMC proliferation and migration and, finally, 
ECM formation. With thrombus formation, there is a release of cytokines and, therefore, stimulation 
of SMC proliferation. There is also an increase in matrix metalloproteinases (MMPs) that facilitates 
the proliferation of SMC and an early macrophage response, which give rise to PDGF, TNF-alpha, IL-
1 and FGF. These cytokines play an important role in SMC proliferation. The anti-inflammatory 
marker CRP is increased after balloon injury and stenting. BMS have shown higher levels of CRP than 
DES following implantation when tested prior to, at 48 hr, at 72 hr and at two-weeks. Inflammatory 
reactions have been shown to increase with increasing medial damage or lipid core penetration by the 
stent, with the amount of restenosis being proportional to the extent of vascular damage and the extent 
of the inflammatory response.  Gaspardone et al. also noted that higher CRP levels were associated 
with higher major adverse cardiac events (MACE), and persistent CRP levels after 48 hrs are 
associated with a greater incidence of restenosis (134). Subsequently, late thrombus formation 
following stent deployment, has led to MI, which has resulted in a loss of confidence in the long-term 
success of vascular stenting (135). 
Animal studies have demonstrated that stent design has an impact on the degree of IH (136), while 
human studies had not been studied in this regard prior to by 2001. Hoffmann et al. conducted a 
human study in 2001, and suggested that the stent design had a significant impact on the development 











is controlled by minimizing endothelial denudation during stent expansion and avoiding stent strut 
penetration of the vessel wall at deployment (137). 
In diabetics, there is an increase in restenosis following PCI (138). Piatti et al. showed that IR and 
endothelial dysfunction together with stenting are early predictors of increased restenosis (139). The 
difference in morphological changes occurring during balloon injury as opposed to stenting includes 
the fact that, when using a stent, one avoids elastic recoil, vessel shrinkage and constriction, but sees 
rather vessel remodeling, increased SMC proliferation and increased NI formation (42). 
The technical aspects of histological analysis of stented vessels have been challenging in the past, and 
limiting factors in the evaluation of restenosis. The development of the technique for resin embedding 
prior to this thesis involved traveling to the UK and USA in order to acquire the skills required. This 
also involved years of research into several different resin formulations that could accommodate our 
histological requirements. This culminated in a publication in collaboration with colleagues in Ottawa 
as a result of the research and development conducted as a preliminary to this study on comparative 
methods of sectioning methodologies of stented material (140) (see attached publication). The success 
in this technical field has made histological analysis of nitinol or stainless steel containing metal 
explants possible. There are two techniques currently in place for this procedure, namely sectioning 
with a tungsten blade on a rotary microtome or using a high-speed saw and grinding technique. 
Minimal damage to the tissue-stent interface occurs using a high-speed precision saw and grinding 
technique, but which is time consuming and results in substantial loss of tissue. Stent struts remain in 
place and undistorted. The bladed technique offers a wider range of special staining due to the fact that 
the resin is removed prior to staining. Occasional scoring or tearing of sections, together with stent 
distortion and displacement, can however occur. This technique results in minimal loss of tissue 
though, and it is possible to do serial sections and, in some instances, Immunohistochemistry. 
4.2 Drug Eluting Stents (DES)  
The DES was introduced in 2001 to address the problem of thrombosis, and for many years, they had 
a significant impact on the reduction of restenosis (141). Late thrombosis represents a major safety 
concern of stenting with at least 10% of BMS cases leading to MI. Studies comparing DES with BMS 
have been controversial, but seem to reflect similar success rates (142). 
DES, containing coatings of Sirolimus or Paclitaxel, have been passed by the federal drug association 
(FDA) after undergoing clinical trials in 2001 (Fig-39). Sirolimus, or Rapamycin, was originally an 
anti-fungal agent discovered in a soil sample on Easter Island (Rapa Nui) (143). It contains potent 
anti-inflammatory and immunosuppressive properties. Paclitaxel, in contrast, is a mitotic inhibitor, 
originally used for the treatment of cancer and now marketed under the name of Taxus (144). 
In 2000 bioabsorbable stents, created from poly-L-lactic acid were used in a human study of 15 











(TLR) were only 10%, making them safe and feasible. There have been and continue to be a multitude 
of DES and dual DES under investigation in an effort to reduce NIH (145). 
 
Figure 39 The structure of Paclitaxel and Sirolimus  
4.3. Materials & Methods  
As in the case of non-stented animals, three groups of Zucker rats chosen for stenting were ZFR-F, 
ZFR-L and ZDF. All the rats that underwent stent implantation were followed up for a 21day period. 
In the ZDF rats, glucose levels were monitored until they reached a level of 10mM before being 
entered into the study.  
The rats were anaesthetized with ketamine/xylazine (200µl/400g; ratio 9:5ml; i.p), together with 
administration of buprenorphine (0.05mg i.m) as a prophylactic analgesic. Heparin (100U/Kg) i.v. was 
administered prior to arteriotomy. Surgery was performed with the aid of a stereomicroscope Nikon 
(SMZ 800). A balloon injury was performed as described previously, and the stent deployed and 
expanded to 8 bar of pressure followed by withdrawal of the balloon catheter. The circulation was 
restored via the ICA by removal of both the CCA and ICA vascular clamps, and the incision was 
closed once homeostasis was ensured. Retrieval of stents took place 21 days post operatively. A 
cannula was placed into the left ventricle and phosphate buffered saline (PBS, pH 7.4 containing 
heparin) was infused using a peristaltic pump. Perfusion fixation was performed with PFA (4% w:v) 
followed by surgical removal of the left and right carotid arteries into 4% PFA for 24 hrs, as described 
in the previous section. 
4.3.1 Resin Embedding & Processing 
Following fixation, stented-carotid arteries were processed manually, through graded alcohols (70%-
100%), toluene, toluene/resin (1:1) and infiltrated with three changes of resin (Resin Solution: 1, II 
and III: 100%) according to the method by Erben et al. (146) (See Appendix A-8). The following resin 











methacrylate (BMA Sigma: 235865); 5ml methylbenzoate (Sigma: M2,990-8); 1.2ml polyethylene 
glycol (Sigma: 20,239-8); Solution II – 100ml solution I plus 0.4g benzoyl peroxide (Sigma-Aldrich: 
228877); Solution III – 100 ml solution I plus 0.8g benzoyl peroxide. Polymerization took place at -
20ºC over 72 hrs to enable slow, cold curing in a solution of 100ml solution III plus 400µl N.N-
dimethyl-P-toluidine (Sigma: D18,900-6). A double embedding procedure was used to ensure that the 
stent remained in a vertical or upright position. The first embedding was into a 1.5ml micro centrifuge 
tube. This was removed by cutting the plastic tube open and the block was re-embedded into a 5ml 
polypropylene tube with a screw cap lid (Fig-41). Polymerization took place under anaerobic 
conditions at 4C°. The resin blocks were cut from the polypropylene tubes and prepared for both saw 
grinding and tungsten carbide blade techniques of sectioning. (Appendix A-8). 
Three cross sections were taken to determine the formation of IH in the centre and at both ends of the 
stent (level b; c & d). In addition to this, a section was taken just before and just after the stent in order 
to determine the extent of IH taking place beyond the stent (level a & e) (Fig-40). 
 
Figure 40 Schematic: Distribution of cross sections through the stent. 
 
 
Figure 41 A: Macro-photograph of explanted right (stented) and left (control) carotid arteries together with 
the aortic arch. B: High magnification of expanded stent within the carotid artery. C: First resin embedding 












4.4  Histology 
A Beuhler IsoMet 5000 high-speed precision saw [Dusseldorf; Germany] was used to cut sections 
(100µm) at a cutting speed of 3200 rpm with a feed advance of 12mm/min. A diamond-wafering blade 
(12.7mm x 0.4mm; Beuhler) was used. Continual water-cooling was employed throughout sectioning 
to reduce heat caused by friction. These sections were finely polished using a Beuhler Metaserve-2000 
grinder [Dusseldorf; Germany] and two grades of sanding paper (600 & 800) grit to an approximate 
thickness of 8-10µm (Fig-42 D-F). This method of sectioning results in an intact, tissue-stent interface 
and undisturbed vascular wall. There is however substantial kerf loss (tissue depletion) due to the 
thick original section, and block preparation. Sections were stained for haematoxylin and eosin 
(Appendix A-8.3.2) and photographed on a Nikon 90i microscope. IA of IH was performed on these 
sections. 
Thin sections using a tungsten blade were cut on a Leica SM 2500 sliding heavy-duty microtome to a 
thickness estimated to be between 5-10µm. Resin is removed using 2 methoxyethyl acetate and several 
special stains including selected immuno-fluorescent stains were performed. Sections were floated off 
onto 40% alcohol at 42°C, and bonded onto glass slides with Elmers glue (Cat No: 60308-Canada) and 
gently rolled with a rubber roller to flatten them (Fig-42 A-C). They were clamped together and placed 
at 60°C overnight to ensure adherence of tissue sections to the slide (140). 
 
Figure 42 The Leica SM 2500, rolling and clamping technique in (A, B & C) and (G) the resulting bladed 
technique stained with Masson’s trichrome. The precision high-speed saw and polishing technique (D, E & 
F) and (H) the resulting saw ground section. 
Note the stent strut displacement & compression in the bladed section
For the evaluation of elastin, SMC and collagen content, thin sections were cut on a heavy duty sliding 












Masson’s trichrome or modified Movat staining. Elastin is clearly stained in black up with Verhoef’s 
elastin stain and muscle could be distinguished from collagen (Appendix A-5).  
• 4.4.1 Image Analysis: 
Image analysis was carried out using Adobe Photoshop 7.0, together with IPTK version 5 plug-ins 
(Reindeer graphics, Asheville, NC). The analysis was done on sections prepared using the saw & 
ground technique in order to preserve the tissue stent interface and avoid folding or scoring of the 
tissue.  
The lumenal area (inside the hyperplasia) was measured, followed by the area inscribed by the IEL 
area and subsequently the EEL area. The areas occupied by stent wires was measured, and subtracted 
from the total IH area. Finally the intimal thickness was measured by finding the centroid of the 
luminal area and drawing perpendicular lines from this point to bisect the stent wires at their 
approximate mid point. Only the line from the stent wire to the edge of intimal hyperplasia was 
measured, reflecting the intimal thickness. This was performed again, now measuring the intimal 
thickness between the stent wires from the centroid of the lumen to the IEL (Fig-43).  
 
 
Figure 43 Image analysis: Measurement of IH area between the stent wires, from the lumen to the IEL in (A) 
and from the lumen to the stent in (B). The area taken up by the stent wires was subtracted from the total IH 
area. 
Image analysis was also performed on sections of the arteries taken just beyond the limit of the stent. 














4.5.1 IH Comparison: 
The presence of a stent reduced the IH quite considerably in all three groups, compared to the un-
stented balloon injured experiments (Fig 45). The intimal thickness after 21 days following stent 
deployment over the three groups was non-significant. The mean intimal thickness between the wires 
(that is from the lumen to the IEL) was (129.8 ± 60.0µm, 120.3 ± 33.2µm and 141.4 ±100.8µm for the 
ZFR-F, ZFR-L and ZDF rats respectively; p=N.S). The intimal thickness over the wires (that is from 
the lumen to the stent wire, but excluding the stent area) was non-significant (79.5 ± 66.3µm, 96.4 
±58.3µm and 95.6 ± 97.6µm). Media thickness too was not significantly different between the groups 
(24.7±3µm, 32.4±5.9µm and 36.2±11.6µm for the ZFR-F, ZFR-L and ZDF rats respectively). The IM 
ratio in the ZFR-L group was significantly higher (5.8 ± 1.6µm) compared to the ZFR-F group (2.8 ± 
.02µm) and in the ZDF group (2.7 ± 1.3µm) (p=0.023). There was no significant difference in vessel 
stenosis between the three groups (35.8 ± 9.0%, 35.1 ± 8.1% and 43.8 ± 15.0%) for the ZFR-F, ZDF 
and ZFR-L rats respectively.  
 
Figure 44 Graphs showing the medial thickness, lumen equivalent diameter, IM ratio and stenosis. 
* The intimal thickness between the wires indicates the thickness from the lumen up to the stent, and the 
intimal thickness over the wires indicates the thickness from the lumen to the IEL (excluding the area of the 












 Figure 45 Stented Carotid artery in A-ZFR-Lean; B-ZFR-F and C-ZDF, sectioned on a high speed precision 
saw, ground and stained for Haematoxylin and Eosin. No damage to tissue-stent interface using this 
technique. (Original magnification 10 x) 
4.5.2 Levels Beyond The Stent.  
Sections were taken from the region beyond the stent from both proximal and distal ends, where there 
was sufficient tissue available, and stained in the same way as the stented sections. Image analysis was 
modified to exclude the presence of a stent. The parameters measured were lumen area, IEL area, EEL 
area and intimal thickness was calculated. 
Comparison of ZFR-L, ZFR-F and ZDF beyond the stent showed a substantial increase in IH on either 
end of the stent (Fig-46). 
Medial thickness was 64.6 ± 10.6µm, 58.7 ± 11.3µm and 68.4 ±8.8µm for the ZFR-F, ZFR-L and 
ZDF rats respectively (p=N.S), a non-significant difference with (p=0.540). The I:M ratio was also 
similar in all groups 0.8 ±0.1, the 1.1 ± 0.7 and 0.6 ± 1 for the ZFR-F, ZFR-L and ZDF rats 
respectively. The extent of stenosis was also not distinguishable 17.3 ± 22.7%, 41.7 ± 14.5% and 30.2 
± 9.3% (Fig-44). 
The lumen equivalent diameter was also similar 821.3 ± 141.2µm, 914.9 ± 250.0µm and 848.2 ± 
112.1µm for the ZFR-F, ZFR-L and ZDF rats respectively (p=N.S). 
 
Figure 46 Levels beyond the stent: A&D - ZFR-L; B&E - ZFR-F; and C&F - ZDF-F Original magnification 












Figure 47 Media thickness, lumen equivalent diameter, % stenosis and I:M ratio graphs as measured on the 
levels beyond the stent. 
4.5.3 Elastin In The Intimal Region: (Stented vs Ballooned)  
In the stented vessels, elastin fibres stained clearly in the intimal region and had started forming dense 
bands of elastin around the SMC, as opposed to elastin fragments that could be seen at an earlier stage. 
This occurred inconsistently throughout the IH, and to varying degrees from one explant to another. 
There appeared to be a decrease in PG staining (in blue), while at the same time an increase in the 
presence of elastin. The balloon injured, non-stented explants also demonstrated the formation of 
dense elastin bands within the intimal region (Fig-48). The extent of this varied between rats, even 
though all time points were kept the same. 
             
Figure 48 Resin embedded rat carotid artery 21 days after stenting showing the presence of elastin in between 













              
Figure 49 Wax embedded rat carotid artery (ZDF) 21 days after balloon injury showing elastin 
forming rows in the intimal region, stained with elastic Masson’s trichrome .  
4.5.4 Inflammation: (Auto fluorescence) 
Macrophages were present 21 days following stent deployment, particularly concentrated around the 
stent strut region. Due to technical challenges relating to resin immunohistochemistry together with rat 
tissue, the rat specific ED 1 immuno stain was not successful on resin embedded rat tissue. Therefore 
polished, saw-ground images were subjected to UV light to visualize macrophages which auto-
fluoresced and which were then assessed microscopically (Fig-50). There were no significant 
differences between the three groups, but there were also no macrophages in the intima or media of 
the non-stented control vessel, in contrast to their stented counterparts.  
Staining for inflammatory cytokines that were performed in the wax embedded balloon injured rats 
were unfortunately not possible on resin sections.  
                               
Figure 50 Auto fluorescent images of thick saw/ground sections showing macrophage auto-fluorescence 
(A) ZFR-L; (B) ZDF; (C) ZFR-F and (D) ZFR-Lean), four different explants in comparison to that of a 













• 1977 - Andreas Gruntzig introduced PCI 
• 1986 - Introduction of BMS 
• 2001 - The development of DES 
• 2009 - In – stent restenosis & thrombosis remains the confounding pathology of coronary                                                
intervention 
The much needed stent industry has experienced many challenges since their inception, including late 
stent thrombosis and restenosis. They have revolutionized the management of CVD with a procedure 
that does not require a general anesthetic and is simple with a much reduced hospital stay. compared 
to CABG. Controversial data exists regarding the benefits of DES over BMS, and while the former 
may be found to lower rates of repeated revascularization, the risk of late thrombosis remains. 
Our findings showed a definite reduction of intimal thickening in ZFR-L, ZFR-F and ZDF rats within 
the area of the stent. There were no consistent differences in the degree of IH between lean and obese 
groups. The expectations of an increase in restenosis previously described in diabetic subjects were 
also not confirmed by our experimental data. In accordance with Jonas et al, our ZDF group instead 
displayed less intimal thickening than the ZFR-L group in balloon injured animals. In the stented 
groups there was no significant difference in the extent of IH.  
There continues to be a macrophage presence in the area adjacent to the stent struts after 21 days, 
presumably in reaction to the foreign material. In spite the ability to perform immunohistochemical 
stains on human and primate tissue using this resin formula, the combination of this resin and rat 
tissue unfortunately did not afford us the opportunity to perform in depth immunohistochemistry for 
inflammatory markers or HSPG.  
The large amount of IH just beyond the stent was an interesting finding. Analysis confirmed that the 
ZFR-F group showed the greatest degree of intimal thickening beyond the stent, although this group 
was not statistically different from the ZFR-L or ZDF groups. 
The sub-endothelial layer separating the endothelium from the IEL is an essential and complex layer 
without which, ECs cannot adequately attach themselves to form a confluent single cell layer. Elastin 
is a major component of the ECM, which is composed of ECM components providing cell with 
adhesive properties to enable adequate EC anchorage. Smooth muscle cell migration & proliferation 
together with ECM formation contribute to the development of intimal thickening. There is a 
substantial amount of elastin present in the intimal region of the artery following angioplasty as 
described by Aoyagi in 1996, when they linked the synthesis of elastin to proliferating smooth muscle 











increased following arterial injury, while Nikkari et al. claimed that elastin synthesis was maximum at 
2 weeks and decreased at 4 weeks after injury (40). Tropoelastin is a precursor protein of elastin, 
which is secreted by fibroblasts and SMCs and assembles to form mature elastin that is cross-linked 
by lysyl oxidase once excreted into extra cellular space. A 1998 study by Forough et al. demonstrated 
that tissue inhibitor metalloproteinase (TIMP-1) over expression in balloon injured arteries modulates 
proteolytic activity which assists in reducing IH. They deduced that MMP cause physical 
manipulation of the vascular wall, which increased elastin accumulation and that the injury to the 
intima of arteries accelerates elastogenesis (148).   
The implications of having a well formed, stable IEL in order to have functional artery, have been 
stressed by Sims, however there are several contributing factors essential to this process, without 
which an injured vessel cannot execute repair and re-endothelialization. 
The use of surface coatings with natural matrix components such as elastin or fibrillin-1 have showed 
that ECs attach poorly onto elastin coated PU or polycaprolactone (PCL) scaffolds, and displayed 
impaired functional properties. Fibrillin-1 coated surfaces had confluent EC monolayer coverage with 
stable functional characteristics, inhibiting SMC migration into vascular graft scaffolds (149). Thus it 
would appear that while a well-formed IEL is absolutely necessary to a healthy vessel, the sub-
endothelial layer between elastin and the EC is of critical importance. This layer is a complex three-
dimensional layer composed of PG and glycoproteins, laid down by the endothelium and is 
responsible for modulation of vascular tone and thrombogenicity, while providing an anchorage for 
cellular interactions. The IEL is composed of not only elastic fibres, but fibrillin microfibrils and PG 
as well. This would suggest that none of these components could operate individually to develop and 
sustain a healthy, functional and stable endothelium. The artery wall is dependent on an intact IEL, a 
confluent endothelium and the presence of a PG rich glycocalyx layer. Several studies have been done 
whereby vascular grafts have been coated with growth factors, heparin, elastin or PG etc in an attempt 
to stimulate development of an in-tact endothelium on the luminal surface, however, there is a need 
for further studies incorporating a combination of these components which are dependent on one 
another in order to endothelialize the inner surface of a vascular graft or stent (150). 
Histologically, the arteries appeared to be well endothelialized and the tunica intima contained 
substantial amounts of elastin, SMC (Actin stain), collagen and PG (Movat Stain). 
This year, 2009, has seen the promising two-year follow up report of the bioabsorbable everolimus-
eluting stent in single de novo lesions (151). The elution of this drug restored the vasodilation and 
vasoconstriction in stented vessels in contrast to first generation stents that demonstrated vessel 
constriction during exercise. In addition this year has seen the development of a computer model by 
Elazer Edelman, a pioneer in drug delivery systems, used to predict stent performance under varying 
conditions. Through the use of computer modeling, this allows changes to stent configuration, 
materials, vessel wall shape and drug flow propulsion to evaluate the distribution of drug in different 












There is much work to be done on stent related complications, and DES are still associated with 
adverse vascular healing and endothelial dysfunction, as well as late thrombosis (142). Our data shows 
that there is clearly a benefit of reduced IH with the use of stenting as one of the treatments for 
vascular stenosis. Ongoing research in this area of technology together with pharmaceutical 
approaches, can only improve its current success in limiting SMC proliferation following coronary 
intervention. 
 













Other Models of Intimal Hyperplasia 
5.1 Introduction 
Just as intimal hyperplasia as a consequence of PCI is analogous to the process of smooth muscle cell 
migration and proliferation in atherosclerotic disease, it is also a consequence of a variety of 
pathological situations. This includes CABG where the SV is used to bypass a diseased coronary 
artery feeding the heart muscle and vein grafting, in which the SV is placed into a peripheral artery for 
similar reasons, arterial stenting, be it endovascular, to relieve occlusion or extra vascular, as a means 
of support for a vein exposed to arterial pressures, likewise exacerbates this process. Trans-
anastomotic ingrowth from the suture lines of a bioprosthetic graft is yet another form of IH, often 
referred to as pannus. Vascular grafting continues to be limited by the development of IH 100 years 
after it was first introduced (121, 122). The sequence of IH formation after balloon injury in PCI has 
similarities to the process that develops following vein grafting, however these two scenarios expose 
the grafted vessels to different haemodynamics and shear forces. Although a vascular graft does not 
undergo the endothelial denudation that occurs during balloon angioplasty, it has been shown to suffer 
a loss of EC within ? 24 hours following surgery (122). There is also a mismatch of elastic properties 
between the vascular graft and the native vessel. A vein that is placed into the arterial position 
becomes exposed to a change in arterial pressure from 0.2 dyne/cm2 to 3-6 dyne/cm2
For the purpose of this thesis, a retrospective analysis of vascular grafts was performed in Chacma 
baboons in a comparable study using externally stented, SV grafts placed in the femoral as well as the 
coronary position in the same animal (152, 153). The extent of intimal hyperplasia was assessed in 
comparison to a non-stented control in the opposite femoral artery of the same animal (A).  
. The resulting 
neointima is composed of around 20% of proliferating SMC with its origin in the media, which in turn 
deposit ECM and which makes up 60-80% of the intima (122).   
A largely unrelated form of IH involving the proliferation and migration of SMC is that of trans-
anastomotic ingrowth following implantation of bioprosthetic vascular grafts. This model also 
stimulates the use of bioprosthetic heart valves. This tissue needs to be stabilized with cross-linking 
agents and is devoid of an endothelium. Bioprosthetic tissue does not respond with sub-intimal SMC 
proliferation due to this cross linking but has the advantage of being immunogenic despite masking of 
the antigenic sites(154).  
Once again in a retrospective study of the use of porcine bioprosthetic tissue implanted into the iliac 
position in baboons, the development of IH originating at the anastomosis through to the luminal 











5.2  Coronary Artery Bypass Graft (CABG), Vein grafting & 
Extravascular stenting 
In this analysis we compared the response to vascular grafting of the SV into the femoral position to 
the externally stented equivalent on the opposite side. The coronary artery underwent CABG using a 
SV with an external mesh support in the same animal. The mesh used in this study was nitinol, (a 
titanium and nickel alloy) 6 weeks and 12 weeks. 
The graft was dissected with at least three representative mid-sections and a longitudinal section at 
each anastomoses as seen in (Fig-51.). One of each stented sample was de-wired and embedded in 
wax and used for immunohistochemitry and one mid-section was embedded in resin and sectioned 
with a tungsten carbide blade. Blocks were already made and were just sectioned and stained as 
described below. 
5.2.1 Material and Methods 
5.2.1.1 Elastic Masson’s Stain 
To assess intimal thickening, 3µm sections were stained for Masson’s trichrome stain to differentiate 
muscle from collagen as well as elastic fibres (Appendix A-5). Images were taken using a Nikon (90i) 
microscope at 4 x magnification, and tiled together to form one image (Fig-51).   
 
5.2.1.2 VWF  
Section (3µm) were cut on a rotary microtome, Microm HM360 and mounted on coated slides. They 
were stained for Von Willebrand factor to detect endothelial cells, using immuno-fluorescent 
techniques (Appendix A-7.1). Pre-treatment with proteinase K (Diagnostech-S-302080 Denmark) for 
20 minutes was used as antigen retrieval followed by overnight incubation with rabbit anti-VWF 
((ab6994 Cambridge; UK) diluted (1:400) in 1% BSA/PBS at 4°C. This was followed by washing in 
TBS and incubation with a Donkey anti-rabbit IgG/Cy 3 (Jackson’s Immunochem;Pennsylvania;USA) 
secondary antibody for 2 hours. Sections were washed in TBS and mounted in Vector-shield DAPI 
mountant and photographed on the Nikon (90i) microscope. 
5.2.1.3 Heparan Sulfate  
Standard immunohistochemical staining for the presence of heparan sulfate (HS) was performed 
(Appendix A-7.2). A monoclonal antibody rat anti-human HS Abcam (ab2501) (Cambridge; UK). 
Proteinase K (Diagnostech-S-302080 Denmark) digestion for 10 minutes was performed to enhance 
antibody staining. Primary antibody incubation diluted in 1% BSA was performed overnight at 4°C. 
Goat anti-Mouse (HRP) bioyinylated secondary antibody (Histomark 71-00-29 KPL-Gaithersburg; 
USA) was used for detection, followed by Streptavidin peroxidase. (Histomark-71-00-38 
Gaithersburg; USA) and Histomark True Blue (Histomark-71-00-68 KPL-Gaithersburg; USA) 
chromogen. Air-dried sections were dipped into xylene, and mounted in Entellan. Images were 











5.2.1.4 Macrophages (CD 68) 
For the detection of macrophages 3µm sections were pre-treated with Proteinase K (Diagnostech-S-
302080 Denmark]) for 10 minutes, before incubation with the primary monoclonal antibody CD 68 
(Diagnostech M0814) for 1 hour at room temperature (Appendix A-7.1). This was followed by 
washing in TBS and incubation with a secondary antibody, Donkey anti-mouse Cy3 
(JacksonsImmunochem; Pennsylvania; USA) for 2 hours. Sections were washed in TBS and mounted 
in Vector-shield DAPI mountant.  
5.2.2 Results 
The control group showed a moderate formation of IH layer beneath the endothelium compared to the 
mesh reinforced groups. In the stented SV there was a significant degree of constriction of lumen 
diameter (Fig51).  
 
Figure 51 Microphotographs of (A) control SV, non-stented placed in the femoral position, (B) externally 
stented SV placed in the femoral position and (C) externally stented SV placed in the coronary position. (D-F) 
elastic Masson’s staining of the same group respectively and (G-H) Von Willebrand Factor on equivalent 
sections with wires removed. Original magnification of microscopic images was 4x. 
 
There was a distinct macrophage absence in the control vessel as well as in the externally stented 











VWF staining confirmed full endothelialization in the control and mesh reinforced groups as well as 
the pre-implant samples. After both 6 week and 12 week time points (Fig-51 and 52). 
  
Figure 52 The pre-Implanted SV shown (A) elastic Masson's staining and (B) VWF fluorescent staining 
showing a full endothelium, as well as adventitial vessels. Original magnification 4 x. 
 
 
Figure 53 IH of cross sectional area showing the majority of hyperplasia occurring in the first 6 weeks (152).  
Immunohistochemical staining of Heparan Sulfate confirmed the presence of an endothelial 
glycocalyx layer on the luminal surface in both femoral and coronary positions of control veins 
without mesh support. The pre-implant sample showed no HS staining throughout the vein wall, but 












Figure 54 Immunohistochemical staining demonstrating elevation of Heparan Sulfate in stented SV in the 
femoral (A) and non-stented SV in coronary positions (B), as well as the presence of the endothelial 
glycocalyx on the luminal surfaces. The pre-implanted SV (C) shows no HS staining in the wall, only in the 
vascular endothelium. Original magnification 20 x. 
5.3  Bioprosthetic Artery graft  
Iliac interpositional, porcine, graft was grafted into the iliac artery of a non-human primate (Chacma 
baboon)  
5.3.1 Materials and Methods 
The study involved grafting a porcine aortic tissue graft into the iliac circulation for 42 days. Wax 
embedded tissue was sectioned (3µm) on a Microm HM360 microtome onto coated glass slides and 
stained. Staining was performed using Elastic Masson’s trichrome stain, anti-heparan sulfate for 
glycocalyx detection, VWF immunofluorescence for endothelium and CD-68/CD-3 double stain for 
inflammatory cells including macrophages and lymphocytes. 
5.3.1.1 Elastic Masson’s Trichrome 
Sections (3µm) were dewaxed and stained using the Masson’s trichrome stain according to (Appendix 
A-5). Images were taken on a Nikon (90i) microscope. 
5.3.1.2 VWF 
Standard immunofluorescent techniques as described in (A-7.1.) were used to demonstrate the 
presence of endothelial cells staining using VWF antibody, in combination with a fluorescent 
secondary antibody. Sections were photographed on the fluorescent microscope (Nikon 90i). 
5.3.1.3 Heparan Sulfate  
Staining for the presence of heparan sulfate (HS) was performed using standard immunohistochemical 
technique (Appendix A-7.2). The Abcam (ab2501), A monoclonal antibody rat anti-human HS was 
applied after Proteinase K digestion for 10 minutes was performed to enhance antibody staining. 
Primary antibody incubation (in 1% BSA) was performed at 4°C, overnight. A goat anti-Mouse (HRP) 











using Histomark True Blue chromogen. Air-dried sections were dipped into xylene, and mounted in 
entellan. Images were captured on a (Nikon 90i) microscope. 
5.3.1.4 Inflammatory Cells 
Double immunofluorescent staining was used to stain both macrophages and T-lymphocytes. The 
method is described in detail in (Appendix A-7.5). The section was incubated with a cocktail of two 
antibodies, namely monoclonal Mouse anti human CD 68 and polyclonal Rabbit anti human CD 3. 
Similarly a cocktail of secondary antibodies was used (Donkey anti-mouse Cy3 and Donkey anti-
rabbit Alexa 488) for detection. Images were captured using a Nikon 90i fluorescent microscope.  
5.3.2 Results 
5.3.1 Hyperplasia 
There was transanastomotic ingrowth originating from the medial tissue, through the anastomosis to 
the luminal surfaces both proximally and distally, extending over both the graft as well as the native 
artery (Fig-55). The pannus layer is made up primarily of SMC and ECM components but in addition 
contained a large population of inflammatory cells including macrophages and lymphocytes.  
5.3.2 Glycocalyx 
There is an extensive glycocalyx layer covering the surface of the hyperplasia as demonstrated by 
immunohistochemical staining of HSPG (Fig-56). The layer of trans-anastomotic ingrowth as well as 
the native artery also demonstrates strong staining for HSPG differentiating it from the surrounding 
adventitial tissue. Vascular endothelial cells can be seen staining positive within adventitia. 
5.3.3 Inflammation 
Double immunofluorescent staining demonstrated an extensive population of macrophages and 
lymphocytes surrounding the entire graft, including the pannus area. Multi-nucleated foreign body 
giant cells were also detected by the double stain (Fig-57). The inflammatory cells were seen to cluster 
at the cut edge of the graft, close to the graft as well as within the pannus. 
       
Figure 55 Elastic Masson's trichrome staining of the anatomosis of a bioprosthetic porcine graft, showing the 













Figure 56 Heparan Sulfate staining showing the positively stained intimal area (IH) and the native artery 
beneath is negative except for the vessels within the wall, with a glycocalyx on its surface. Magnification 20 x; 
40 x; 60 x and 4 x. 
 
Figure 57 Double immuno-fluorescence of CD 68 positive macrophages in (Cy 3) and CD 3 positive 
lymphocytes in (Alexa-488) in the pannus edge covering the a-cellular porcine graft. Nuclei are stained with 












Taking into consideration the points listed below, a comparison was drawn between the three studies 
described. 
• The absence of obesity as a contributory factor to the development of hyperplasia in a different 
animal model and the absence of a pre-existing pro-inflammatory state compared to that found in 
the obese and diabetic rats. 
• The re-endothelialization that occurs following angioplasty as opposed to the transplant of a living 
endothelium in a vein graft. 
• The significance of an external mesh support on IH considering that the vein is in an arterial 
position under greater pressure. 
• The presence of an endothelial glycocalyx as described in the balloon angioplasty study. 
• The existence of a mismatch of elastic properties between the vein graft and the native vessel. 
Given the fact that this study was conducted on non-human primates without the presence of obesity 
or MS, we cannot directly compare the result from balloon angioplasty /stenting in rats with these 
results. We can however, compare the overall results from the ZFR-L rats (both reinforced and non-
reinforced) to these findings. For the purpose of this comparison the table below simplifies the various 
groups (see Table below). 

























5.4.1 Bioprosthetic Artery Graft. 
The porcine bioprosthetic graft in the iliac arterial position in a non-human primate shows extensive 
transanastomotic IH, characterized by strong HSPG staining throughout the pannus region. There is 
also an extensive endothelial glycocalyx present along its entire length. The pannus (area of IH) has 
complete endothelial coverage as confirmed by VWF staining. This is in keeping with the findings 
seen after carotid balloon injury in the lean Zucker rat. These two models differ with regard to their 
inflammatory response, as there is a widespread population of inflammatory cells surrounding the 
bioprosthtic graft, as well as in the pannus area, but which is not seen following balloon injury in the 











was mild in comparison with the extensive response associated with the bioprosthetic graft. This is in 
spite of decellularization of the graft prior to implantation, that was expected would render it less 
immunogenic.  
Although the bioprosthetic graft may present a suitable non-thrombogenic lumenal surface the 
transanastomotic ingrowth and inflammatory response remain a concern. 
5.4.2 Reinforced SV grafts in CABG 
The findings in Chapter 3 and 4, which relate to the degree of IH in the stented carotid artery in the rat 
model, show decreased IH compared to non-stented balloon injury. This confirms the results in this 
Chapter when comparing stented SV to non-stented SV grafts. The long-term patency of SV grafts is 
significantly improved by the use of external mesh reinforcement (153). The external mesh reduces IH 
by decreasing flow shear stress changes caused by size mismatch of a vein joined to an artery as well 
as eliminating lumenal irregularities, thereby reducing turbulent blood flow. The histological findings 
of this study confirm the presence of an endothelium in pre-implanted SV, implanted non-stented SV 
as well as stented SV in both femoral and coronary positions, as was the case in the balloon injury 
groups. This suggests that the physical presence of an endothelium, although advantageous, indeed, 
may not be the necessary criteria for prevention of IH, the question of its viability at the time of 
reperfusion could be a consideration. Zilla et al. found that the presence of an external mesh around 
the SV was responsible for the decrease in IH in comparison to the non-stented SV (153). This finding 
was in spite of both SV being completely endothelialized. There is a noteworthy low presence of 
inflammatory cells in the SV grafts, both stented and non-stented, similar to what was confirmed in 
the balloon injured rat. This may be explained by the absence of a pre-existing underlying vascular 
disease that one would encounter in a clinical scenario, or due to the time point defined by our studies. 
The presence of inflammatory mediators as characterized by CRP staining, confirms the role of an 
inflammatory response, even if direct evidence of this is lacking at the time point chosen. 
In conclusion, the IH demonstrated by SV grafts and bioprosthetic artery grafts continues to stimulate 












The emergence of novel techniques to overcome the limitations of PCI are welcome developments in 
cardiac surgery amidst the overwhelming burden of chronic disease and the high percentage of 
revascularization requirements following balloon angioplasty and vascular stenting. Coronary artery 
disease is expected to account for 14.2% of all deaths by 2030, and healthcare budgets are buckling 
under the load of expensive technology and follow up treatment (155). 
Previously, CABG introduced in the 1960s, represented the conventional treatment for coronary artery 
disease. Subsequently the introduction of PCI in 1977 by Andreas Gruntzig, changed the course of 
management of heart disease. This brilliant development represented a major accomplishment of 
twentieth century medicine and became a widely used alternative to open heart surgery. This period of 
euphoria was short lived, as new problems began to emerge. Between 35%-40% of patients required 
single or even multiple repeat procedures due to the development of restenosis by IH and introduced 
the serious risk of acute coronary occlusion or thrombosis of the coronary artery, often resulting in MI 
or death, and which required emergency CABG. Lastly, there was the realization that the intervention 
did not alter the natural history of the disease (156). 
The introduction of BMS in 1986 reduced stenosis to 20%-25%, but along with this breakthrough, 
came the complication of late stent-thrombosis. This was partially relieved in 2001 by the 
development of DES. However, the anti-proliferative coating used on stents was found to inhibit re-
endothelialization (156). 
Currently some of the most common surgical options for the treatment of coronary occlusion include 
balloon angioplasty, CABG (vein or prosthetic grafts) and stenting. These techniques all offer 
temporary relief of the occlusion caused by vascular disease, BUT they all ultimately result in the 
continued development of neointimal hyperplasia.  
The question remains - What to target? Atherosclerosis, MS, Obesity or IH? 
Obesity increases the level of IH following PCI. This has been previously established (14, 157, 158). 
What is the compounding effect of obesity, and is a person of normal weight with atherosclerosis at 
less risk than an obese person with atherosclerosis? Does DM2 contribute to this increased risk? These 
questions are central to the ironic situation, in which the very treatment for stenosis, itself results in 
restenosis, and largely without answers.  
The compounding effect of obesity includes several factors that influence the increased risk for 
adverse outcomes in cardiovascular related complications of obese individuals.  
Obesity induces a pro-inflammatory state that exacerbates cardiovascular complications as well as 
leading to IR and even to EC dysfunction. Wall shear stress increases with increase in body fat (49) 











resulting metabolic changes. Pathological changes of beta cell dysfunction are directly related to 
complications of obesity and DM2. Decreased mRNA adiponectin, together with increased TG, 
insulin, glucose, plasma LDL, FFA and importantly, the enzyme, heparanase occur in DM2.  
Our findings confirm the definite correlation between obesity and IH. Increased body fat in ZFR-F rats 
resulted in an increase in post angioplasty neointimal hyperplasia in comparison to the ZFR-L control 
group. The obese ZDF group unexpectedly displayed substantially less IH than the ZFR-L group. 
Although this group could not be defined as being frank, glucose intolerant, diabetics, as they were not 
severely hyperglycemic, pathological changes to the islets of the pancreatic islets were nevertheless 
observed confirming insulin resistance. Previous investigators (99) encountered this same finding in 
ZDF rats, as well as in Sprague-Dawley diabetic rats. This was explained by the fact that the 
phenomenon could possibly be due to severe hyperglycemia, resulting in the observed weight loss. 
This was not, however the case in our ZDF group in this study whose weights were similar to the 
ZFR-F group and at most these animals were only mildly hyperglycemic. Other investigators have 
obtained similar findings of decreased IH in severely hyperglycemic diabetic groups (106, 159, 160). 
Schiller et al. suggested that reduced intimal thickening could be as a result of increased EC regrowth 
or normalization of EC phenotype. In that study diabetic animals showed a greater endothelial 
regrowth albeit with impaired EC function. The idea that re-endothelialization inhibits IH 
development is not new, but adds support to the possible use of therapeutic agents that improve re-
endothelialization. Their data suggested that hyperglycemia and decreased insulin levels could play a 
role in reducing IH through stimulation of EC regrowth. It may be possible that re-endothelialization, 
even in the presence of impaired physiological function, would help to inhibit neointimal thickening 
(160).  In contrast, Von Willebrand staining for endothelium in our study showed complete (90 - 
100%) endothelialization in most samples of ZFR-F, ZFR-L and ZDF groups. Thus, our finding that 
was that neointimal hyperplasia was not inhibited, in spite of full endothelial regrowth.   
Diabetes and obesity is associated with a low-grade inflammatory state. The hypothesis that this 
inflammatory state may be a contributory factor in the development of vascular disease, and possibly 
increase IH following injury, was based on this premise. Our investigation into the effects of injury on 
several inflammatory cytokines and the possible correlation to IH interestingly, showed elevated 
staining for adiponectin in the ZDF followed by the ZFR-F and then the ZFR-L groups. In spite of the 
fact that adiponectin is believed to be protective against inflammation and decreased in obese and 
diabetic individuals, the findings in this study were not in agreement. There were also high levels of 
staining for CRP in our ZDF group, that confirm the existence of an underlying pro-inflammatory 
state, since CRP is a predictive marker for cardiovascular disease (35). CRP staining in the ZFR-F and 
ZFR-L were relatively high, but less than in the ZDF group.  
Our finding of elevated CRP levels in the ZDF group post angioplasty confirms the existence of a 











obesity are greater CV risk factors and are accompanied by increased CRP plasma levels (108). 
According to Virmani, raised CRP levels are a prominent finding in atherosclerotic lesions (161). 
There was however a zero to low level of staining for IgG in the ZDF group compared to the ZFR-F 
group, which was strongly positive in some rats, primarily in the intimal region. Of interest, was the 
result of IgA staining associated with the endothelium of balloon-injured arteries in the ZDF group 
and negative in the ZDF group. Secondly, when either sera from a balloon injured or non-injured rat 
were compared when applied to different sections from the above groups that originally stained 
positive for IgA in the intima and adventitia but not in the media, the media subsequently also stained 
positive for IgA. This suggests that an immune response could be responsible for the activation of 
SMC proliferation. Further evidence for this comes from a study by Soleimani et al, in which 
alloantibody was found to be responsible for enhanced SMC proliferation following carotid artery 
transplantation in mice. This was completely absent from B lymphocyte deficient mice (162).  
The time point defined in our study, although selected to discern primarily the extent of vessel 
stenosis, was not ideal for the analysis of inflammatory cells, as macrophages and neutrophils 
typically infiltrate the injured area three to seven days post injury and decreasing thereafter (163). The 
lack of inflammatory cells in the intimal hyperplasia region of the balloon injured arteries suggests 
that inflammation possibly was not driving force behind this process, although it may have contributed 
towards it in the early stages of IH development following injury. Our stented group, however showed 
the presence of macrophages at 21 days located specifically in the region of the stent struts in response 
to the foreign material. This confirms previous findings (98, 164). Several studies have associated 
inflammation with post PCI restenosis, and which have implicated macrophages in the development of 
IH (134, 164, 165). The response to injury caused by balloon angioplasty differs from that of vascular 
stenting in that there is only an early neutrophil response and according to Rogers, is devoid of 
macrophages (166). Following stenting there is a sustained macrophage presence in the intima. Future 
studies evaluating the effect of inflammation on restenosis could provide much needed therapeutic 
information for the possible use in DES. 
The use of methacrylate resin to facilitate sectioning and preservation of the stent-strut interface 
introduces problems for immunohistochemistry. Although it certainly is possible to perform 
immunohistochemistry on certain resin embedded tissue, it is not necessarily a given. Although much 
research has been carried out by our laboratory into this subject and the resin used in this project was 
suitable for immunohistochemistry techniques on human and baboon tissue, we encountered some 
difficulties on rat tissue with certain antibodies, specifically ED-1 (macrophage marker). In spite of 
antigen retrieval techniques and modified incubation times, this combination of rat tissue embedded in 
methacrylate resin did not allow accurate staining for this antibody. 
Our findings of the I:M ratio (1.4) in the obese groups were in keeping with those previously reported 
(Desouza-1.4; Shelton-1.37 and Park-1.6), however our I:M ratio in the stented lean group (1.0) was 











increase in the tunica intima, but rather by the decrease in the medial thickness. This finding of a 
thinner media in lean rats seems to be confirmed by Park and Shelton. It is interesting to note that the 
medial thickness of the ZFR-L group is lower than the ZFR-F and ZDF groups in all three scenarios, 
namely following balloon injury, stented balloon injury as well as in the levels, which extended 
beyond the stent.  
In the stented study, intimal thickening was controlled by the presence of the stent, and the increase in 
IH at proximal or distal ends beyond the stent substantiated this finding. A stent may provide a 
treatment for occlusion due to stenosis or atherosclerosis and result in re-endothelialization within the 
stent region, but the resulting neointimal thickening beyond the stent must result in WSS changes that 
impact vascular tone and mechanotransduction. These findings support Schiller’s hypothesis that EC 
regrowth may in fact attenuate IH development, however the areas beyond the stent would suggest 
otherwise. The EC remains a key and vital player in modulating the proliferation and migration of 
SMC following vascular intervention. There are relatively few studies available on stented carotid 
arteries in Zucker rats, but our findings relating to the absence of variation in intimal thickness 
throughout the three groups confirms the finding by Jonas et al.(99), however, the reason for this is 
still unclear, and further investigation would be beneficial in this regard. 
We did not assess the shear stress changes in this study. However, the influence that diameter changes 
have on the flow of blood through an artery cannot be ignored. The role of shear stress changes within 
the vessel has been addressed by several investigators (48, 50, 114, 167, 168), and has been shown to 
have an effect on the development of IH. The effects of wall shear stress (WSS) on EC function have 
been well described (48, 49), and have been shown to stimulate the production of endothelial 
glycocalyx. Dimensions of glycocalyx are reduced at atherosclerotic prone lesions (51), and this could 
explain why glycocalyx dimensions are reduced at bifurcations that experience a reduced WSS. 
Therefore the EGL is considered to be the first step in the process of mechanotransduction(49). Both 
high and low WSS is believed to be responsible for glycocalyx disruption, and it may therefore be 
necessary for an optimum WSS to maintain EC function (67). 
In addition, experiments on WSS have mostly been conducted in vitro, based on average calculated 
WSS, whereas in vivo shear stress varies along the arterial tree. The mean WSS in man is 0.5 Pa 
compared to 7.0 Pa in rats and 8.8 Pa in mice. This may be due to the decreased arterial diameter in 
smaller animals with a blood velocity comparable to larger animals (169) This has implications on 
previous experiments related to WSS with assumptions for mean WSS being inaccurate. 
The endothelium was for many years seen to be the barrier between the vascular wall and the blood 
flow. More recent investigations into the presence and role of the endothelial glycocalyx have altered 
this perception. Improved techniques to quantify or visualize this layer have shown it to be larger than 
first imagined. It has also been shown to be vitally involved in the vascular permeability and 
maintenance of vascular tone. Changes to this meshwork of glycoproteins and PG appear to be the 











endothelium seems critical for control of IH post angioplasty, but it is the glycocalyx that senses and 
translates environmental changes to the cells below it. 
One of the important components of the IH tissue are PG. The Movat pentachrome stain 
conventionally detects GAGs or mucins in formalin fixed, paraffin embedded tissue. Alcian Blue is 
specific for acid or low pH, sulfated mucins. We therefore performed a Movat stain on our explants 
balloon injured as well as our stented explants. Our data showed relatively low concentrations of PG 
in the IH region, however there was more positive staining in the stented, resin embedded samples 
than after balloon injury alone. Recent studies into the role of PG and the glycocalyx prompted us to 
further investigate the presence of PG, using the more specific immunohistochemistry technique. 
Chondroitin sulfates are the most prevalent PG stained by the Movat staining and since strong staining 
was not present, HS was selected, as it makes up between 50-80% of the glycocalyx. Strong staining 
for HS was found in the intimal and medial regions as well as demonstration of the glycocalyx on the 
lumen in some samples. 
Several PG have been isolated as playing important roles in mediating the proliferation and migration 
of VSMC, such as perlecan, HA, versican, decorin and heparan and chondroitin sulfate (32, 53, 55, 60, 
167). GAG changes have been noted to take place before changes in SMC phenotype, and this is 
believed to be central to the formation of IH (170). A study of HS and syndecan-1 levels at surgery 
showed huge multifold increases with ischemic perfusion alone resulting in EGL components being 
shed into the circulation, and this could be a trigger for post-operative inflammation (114). Gouveneur 
demonstrated that HA is incorporated into the glycocalyx in response to WSS (50). Baker showed that 
in DM2 there is an increase in CS at the expense of HS, and perhaps this could explain why our ZDF 
group demonstrated a negligible glycocalyx since it is primarily composed of HS (171). 
The increase in the enzyme heparanse is the one parameter in which there is a very strong correlation 
to increased IH (171). HSPG modulate VSMC proliferation, and are essential to counteracting the 
neointimal response to injury. Increased heparanse expression results in increased neointimal 
thickness. This heparanase is expressed in the EC themselves and is regulated by high glucose and 
oxidized LDL levels, and is increased in obese, hyperlipidaemic Zucker rats compared to Zucker lean 
rats (171). Unfortunately it was beyond the scope of this study to include the study of over-expression 
of heparanse on SMC proliferation and migration, but further studies in this regard would be valuable 
in the future. 
It has been proposed that HS maintains SMC in a contractile phenotype and that the presence of GAGs 
and HS reduce the proliferation and migration of SMC in vitro (53). Neointimal hyperplasia has been 
shown to be decreased following administration of HS. With this in mind, perhaps it is relevant that 
platelets and inflammatory cells release heparanase, which degrades HS chains (171). Therefore one 
could say that once inflammatory cells and platelets have resolved, there is an up-regulation of HS and 
thus the resultant dense layer of EGL demonstrated at 21 days post injury together with a gradual 










protective mechanism to handle the changes in shear stress created by a thickened neointima. Perhaps 
the reduced EGL reported in humans due to hyperglycaemia, may result in higher restenosis rates 
following PCI. Takagi et al reported that IH after stent deployment in human patients with glucose 
intolerance is greater than those with normal glucose levels.  
The primary weak link between a healthy vasculature and disease appears to be the endothelial cell. If 
we consider the cascade of events that results from either atherosclerosis or EC injury i.e. glycocalyx 
disruption; EC dysfunction; shear stress changes; release of inflammatory cytokines; decreased NO 
availability; SMC proliferation; ECM development and thrombus formation, they are ALL directly 
linked to, and reliant on, the EC and, if we take it one step further, to the endothelial glycocalyx which 
is responsible for sensing and transducing shear stress to the EC (49). 
Further investigation into the vital role played by the EC, reveals that one of their many important 
functions seems to revolve around the synthesis and secretion of PG. These seemingly unimportant 
substances play a fundamental role in modulating vascular tone; vascular permeability; lipid 
accumulation; inflammation; mechanotransduction and most importantly glycocalyx integrity. FSS 
has been shown to stimulate the incorporation of HA in the endothelial glycocalyx that may contribute 
to enhanced EC function (50). 
The IH due to vascular intervention from PCI, CABG or vein grafting may all have similar origins. 
Beginning with a diseased artery with an underlying pro-inflammatory state, leading to vascular 
stenosis and shear stress changes. Glycocalyx disruption follows with loss of vascular tone and 
endothelial damage. The consequent release of cytokines, growth factors and PG and activation of the 
coagulation cascade triggers the formation of IH. The ultimate mechanical intervention itself promotes 
vascular damage, stimulation SMC migration and proliferation as part of the healing process and 
development of restenosis.  
In spite of an abundance of research and publications in this regard, we are still without a definitive 
solution to this pathology. Further investigation in pursuit of advanced therapeutic intervention is 
required in this essential area of research. 
 
















A.1-10% Buffered Formalin (PBS) 
PBS (pH7.6) Volume 5L 
Table A-1 
Constituent Supplier 
42 g sodium chloride [143 mM] Sigma-S7653 [Steinheim; Germany] 
6.4 g disodium hydrogen orthophosphate [9mM] Merck-Art6346 [Gauteng; SA] 
0.7 g sodium dihydrogen orthophosphate anhydrous 
[1mM] 
Merck-Art 6346 [Darmstadt; Germany] 
For 10% buffered formalin, make up 1 part formalin:9 parts PBS. 
A.2-4% Para formaldehyde (100ml) 
Table A-2 
Constituent Supplier 
4 g Paraformladehyde 95% Sigma-Aldrich 15,812-7 [Steinheim; Germany] 
90 ml PBS (Table A-1)  
Heat gently to 58-60C under a fume hood, but do not overheat. Add 5-10drops NaOH to clear 
solution. pH to 7.0-7.5, make up to volume 100 ml with PBS (Table A-1) 
A.3-Tris Buffered Saline (TBS) Volume 5L 
Table A-3 
Constituent Supplier 
30.3 g tris HCl (trizma) [38.5mM] Sigma-T5941 [Steinheim; Germany] 
6.95 g tris Base [11.5mM] Sigma-saarchem 611 60 00 [Krugersdorp; SA] 
43.83 g sodium chloride [150mM] Sigma-S7653 [Steinheim; Germany] 












A.4-Haematoxylin and Eosin Stain 
A.4-1 Mayers Haemotoxylin  
Table A-4.1 
Constituent Supplier 
2 g haematoxylin Merck-SAAR2822000CB[Gauteng; SA] 
50 g potassium alum Saarchem-111 80 00[Gauteng; SA] 
0.2 g sodium iodate UnivAR 582 34 80[Krugersdorp; SA] 
1 L double distilled water  
1 g citric acid Saarchem-160 5020EM[Gauteng; SA] 
50 g chloral hydrate Saarchem-159 15 00[Gauteng; SA] 
Combine the first four constituents in the Table A-4 and gently heatin a warm bath at 37°C. Add the 
rest of the constituents and boil for 5 minutes. Cool and filter and store in a glass bottle at room 
temperature. 
A.4-2 Eosin/Phloxine 
Table A-4.2  
Constituent Supplier 
1 g eosin Merck-341972Q [Poole; UK] 
1 g phloxine  Merck-1.115926.0025[Darmstadt; Germany] 
Few drops acetic acid Radchem-A032 [SA] 
1 L double distilled water  
Place sections into the haematoxylin solution (Table A-4.1) for 5 minutes and then 5 minutes in 
running tap water to stain the nuclei blue. Place slides in running tap water for 5 minutes, to 
differentiate the haematoxylin. Place the sections into the eosin/phloxine (Table A-4.2) for 30 seconds 
and dip in distilled water followed by dehydration through graded alcohols, 3 changes of xylene and 















10% alcoholic haematoxylin Merck-SAAR2822000CB [Gauteng; SA] 
10% ferric chloride Merck-234 05 00 EM [Gauteng; SA] 
Lugol’s iodine solution (neat) Merck-322 29 83 KF Steinheim; Germany] 
100% alcohol Illovo [Merebank; SA] 
All the constituents were added in equal quantities. 
Acid Fuchsin Solution 
Table A-5.2 
Constituent Supplier 
0.5 g acid fuchsin Merck-250 10 00 [Krugersdorp;SA] 
0.5 ml glacial acetic acid Radchem-A032 [SA] 
100 ml double distiller water  
Phosphomolybdic Acid Solution 
Table A-5.3 
Constituent Supplier 
1 g phosphomolybdic acid Sigma-P7390 [Steinheim; Germany] 
100 ml double distilled water  
Ligh Green Solution 
Table A-5.4 
Constituent Supplier 
2% light green Sigma-L1886 [Steinheim; Germany] 
1% acetic acid Radchem-A032 [SA] 
 
Dewax sections through xylene, graded alcohol to water. Cover with Verhoeff’s solution (Table A-











excess black, leaving only the elastin stained black. Immerse sections in Acid Fuchsin solution (Table 
A-5.2) for 5 minutes and rinse in water, followed by incubation in Phosphomolybdic acid solution 
(Table A-5-3) for 5 minutes and rinse in water. Apply Light green solution (Table A-5.4) for 1 minute 
and rinsed in water before rehydrating and mounting in entellan. 
Results:  
The muscle tissue-stained pink/red 
Collagen-blue/green  
Elastin and nuclei-black. 
A-6-Movat (Modified) 
Alcian Blue Solution 
Table A-6.1 
Constituent Supplier 
1 g alcian blue  Merck-K24319334 [Gauteng; SA] 




10 ml (25%) ammonia solution BDH BB100115Q [Gauteng; SA] 
40 ml 95% alcohol Illovo [Merebank; SA] 
Von Gieson Counterstain 
Table A-6.3 
Constituent Supplier 
100 ml picric acid Fluka 80456[Steinheim; Germany] 
10 ml 1%  acid fuchsin  Merck-250 10 00 [Krugersdorp;SA] 
Bring to the boil and cool before bottling. 
Take sections to water. Treat with Alcian blue table (Table A-6.1) for 30 minutes in a coplin jar. Wash 
slides in running tap water for 10 minutes. Treat with solution in (Table A-6.2) for 3 hours. Wash 
slides for 20 minutes in running tap water. Stain with Verhoeffs solution in (Table A-5.1) for 
30minutes. Rinse briefly in water. Differentiate in 2% ferric chloride until the elastin stains black with 
nuclei slightly lighter. Wash slides in water for 15 minutes. Counterstain with solution in (Table A-












Muscle –yellow; Collagen-pink; Elastin-black; Fibrin-red; GAGS-blue 
 
A-7-Immuno-staining 
A-7.1-Standard Immunofluorescent Staining  
 















K0211684 N/A 1:50 Donkey X Goat/Alexa 488 (1: 
500) 





MCA 341R Proteinase K  
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Ab828 500 Pressure cook; 
Citrtate 
Buffer pH 6 






Diagnostech M0814 Proteinase K 10 
minutes 
1:100 Goat anti-mouse Alexa 488 
[ Invitrogen, Ca,USA] 
 
i) Sections (3 µm) cut on a Microm rotary microtome [HM 360Waldorf; Germany], float sections onto 
warm water before picking them up on a coated glass slide [Marienfeld-Histobond-Germany]. 
ii) Place slides on a 60°C hot plate for 1 hour. De-wax in xylene (3 changes), followed by alcohol (3 











iii) Perform antigen retrieval as required for each specific antibody (Table A-7.1.1) using enzyme 
treatment, Proteinase-K (Diagnostech-S-302080; Denmark) or Protease XIV [Sigma P5147-1G; 
Germany] at 37°C.  
iv) Rinse in running tap water, then place in TBS for 10 minutes.  
v) Incubate sections with primary antibody, appropriately diluted in 1% BSA in PBS for 1 hour at 
37°C (Table A-7.1.1). 
vi) Rinse in TBS for 5 minutes with a magnetic stirrer. 
vii) Incubate with fluorescent secondary antibody directed at the host in which the primary antibody is 
made, in the appropriate dilution in 1%BSA in PBS for 2 hours (Table A-7.1.1).  
viii) Rinse in TBS for 5 minutes, mount in Vectorshield-DAPI mountant  [Vector H1200 Ca;USA], 
seal the edges with nail varnish and view slide under fluorescent microscope. 
A-7.2-Immunohistochemical Staining (Heparan Sulfate) 
i) Cut 3 µm sections on a Microm rotary microtome [HM 360 Waldorf; Germany] [float sections onto 
warm water before picking them up on a  coated glass slide [Marienfeld-Histobond; Germany]. 
ii) Place slides on a 60°C hot plate for 1 hour. De-wax in xylene (3 changes), followed by alcohol (3 
changes) and into running tap water. 
iii) Perform antigen retrieval using enzyme treatment, Proteinase-K [Diagnostech-S-302080 
Denmark] for 10 minutes at 37°C. 
iv) Incubate slides in (3% Hydrogen Peroxide/methanol) for 10 minutes, to block endogenous staining 
of HRP. 
v) Incubate with Mouse Anti-Rat Heparan Sulfate [ab 2501-Cambridge;USA], diluted 1:400 in 1% 
BSA/PBS for 24 hrs at 4° C in a sealed container. 
vi) Rinse in TBS for 15 minutes. 
vii) Incubate with secondary antibody Goat Anti-Mouse Biotinylated IgG [Histomark 71-00-29 KPL-
Gaithersburg;USA] for 30 mins, followed by a 5 min rinse in TBS, and incubation with Streptavidin 
Peroxidase (Histomark-71-00-38) for 30 mins. Rinse in TBS for 5 mins. 
viii) Apply True Blue Peroxidase Substrate [Histomark-71-00-68 KPL-Gaithersburg;USA], un-diluted 
for 5 mins until colour development is complete. Rinse briefly in water. 
ix) Counterstain in 0.25% Neutral Red [Merck 442 60 00CB; Gauteng; SA] for 20 seconds only, rinse 
in water. 












A-7.3-Double Immunofluorescent Staining (Confocal Microscopy) 
i) Place freshly explanted tissue directly into HEPES buffer (A-8.4), without prior fixation. 
ii) Incubate in sufficient Proteinase K [Diagnostech-S-302080; Denmark] to cover the tissue for 10 
minutes with agitation, at 37°C. Rinse well in running tap water. 
iii) Incubate with primary antibody cocktail (Rabbit Anti Human VWF; [Diagnostech M0616; 
Denmark ] 1:100; Mouse Anti Rat Heparan Sulfate; [Abcam-ab2501; Cambridge;UK];1:400 diluted 
in 1% BSA/TBS, for 2 hours with agitation. 
iv) Rinse well in TBS. 
v) Incubate with secondary fluorescent antibody cocktail (Donkey Anti-Rabbit Cy3 1:700 [Jacksons 
Immunochem; Pennsylvania;USA] / Goat Anti-Mouse Alexa 488 1:500 [Invitrogen; Ca; USA]) in 
PBS for 2 hours with agitation. 
vi) Rinse well in TBS for 15 minutes. Transfer sample onto a slide with a spacer, in HEPES buffer, 
and cover with a cover slip. View sample using a confocal (Zeiss) microscope using appropriate 
filters. 
A-7.4-Immunohistochemical staining (Insulin) 
i) Sections (3 µm) are cut on a Microm rotary microtome (HM 360Waldorf; Germany), float sections 
onto warm water before picking them up on coated glass slide (Marienfeld-Histobond-Germany). 
ii) Place slides on a 60°C hot plate for 1 hour. De-wax in xylene (3 changes), followed by alcohol (3 
changes) and into running tap water. 
iii) Perform antigen retrieval using 10 minutes enzyme treatment, Proteinase-K (Diagnostech-S-
302080; Denmark) at 37°C. Rinse in running tap water. 
iv) Incubate with the primary swine anti guinea-pig Insulin (A0564 Diagnostech, Denmark) diluted 
1:400 in 1% BSA in PBS, overnight at 4°C. 
v) Wash well in TBS. 
vi) Incubate in biotinylated Goat anti-rabbit IgG (Histomark: 71-00-30-KPL, Gaithersburg,MD), for 
30 minutes at room temperature. Wash well in TBS. 
vii) Incubate in Streptavidin-peroxidase (Histomark: 71-00-38-KPL, Gaithersburg,MD) for 30 
minutes and wash well in TBS. 
viii) Add chromogen True Blue-HRP (Histomark: 71-00-68-KPL, Gaithersburg,MD) until colour 
change, about 5 minutes. 
ix) Do not take through alcohol solutions, counterstain in .25% neutral red for 5 seconds. Rinse 












A-7.5 Double Immuno-Fluorescence 
i) Sections were dewaxed through xylene and brought to water. 
ii) Antigen retrieval was performed using the pressure cook technique, for 2 minutes, followed by 
washing in running tap water. 
iii) A combination of antibodies was applied in their appropriate dilutions (in 1% BSA). Mouse anti-
human macrophage, CD 68 (M0814,Diagnostech, Denmark) and Rabbit anti human CD 3 (ab818-500 
Cambridge;USA) for 1 hour at room temperature. 
iv) Sections were washed in TBS before incubation with a secondary combination, donkey anti 
rabbit/Cy 3 (Jackson’s Immunochemicals, Pennsylvania, USA) and (Goat anti mouse Alexa 488 
(Invitrogen, Ca, USA) diluted 1:500 in 1% BSA for 2 hours. 
v) Sections were washed in TBS, followed by mounting in Vector shield, dapi mountant. (Vector 
H1200 Ca;USA), and visualized using a triple band filter, Nikon 90I, microscope. 
A-8-Resin Processing, Embedding and Staining Schedule 
Tissue was harvested and fixed according to protocol, for 24 hrs in 4% Para formaldehyde as 
described in A-2.  
A-8.1-Methylmethacrylate/Butyl Methacrylate Resin 
Step No Solution Conc Time(hr:min) Temp(C) 
1 ethanol [Illovo;SA] 80% 30 min 4°C 
2 ethanol [Illovo;SA] 80% 30 min 4°C 
3 ethanol [Illovo;SA] 90% 30 min 4°C 
4 ethanol [Illovo;SA] 90% 30 min  4°C 
5 2-propanol [Gauteng; SA] 100% 60 min  4°C 
6 2-propanol [Gauteng; SA] 100% 60 min 4°C 
7 toluene [Gauteng; SA] 100% 60 min 4°C 
8 toluene[Gauteng; SA] 100% 60 min 4°C 
9 toluene-resin sol 1 50% 60 min 4°C 
10 resin –sol 1 Pure Overnight 4°C 
11 resin – sol 1 Pure All day 4°C 











13 resin – sol 2 Pure All day 4°C 
14 resin – sol 3  Pure Overnight 4°C 
15 resin – sol 3 Pure All day 4°C 
16 Polymerization mixture   -18°C to -20° C 
Glass vials are completely filled with polymerization mixture to exclude air, capped and transferred to 
a deep freezer. 
Polymerization is carried out at -18 to – 20°C and completed within 3 days. 
A-8.1.1-Solution 1 
60 ml methyl methacrylate: Sigma-Aldrich M5,590-9 [Steinheim; Germany] 
35 ml butyl methacrylate: Sigma-Aldrich 235865 [Steinheim; Germany] 
5 ml methylbenzoate:Sigma-Aldrich M2,990-8 [Steinheim; Germany] 
1.2 ml polyethylene glycol 400: Sigma-Aldrich 20,239-8 [Steinheim; Germany] 
A-8.1.2-Solution 2 
100 ml of Solution 1 
0.4 g benzoyl peroxide: Sigma-Aldrich 228877 [Steinheim; Germany] 
A-8.1.3-Solution 3 
100 ml of solution1 
0.8 g benzoyl peroxide : Sigma-Aldrich 228877 [Steinheim; Germany] 
A-8.1.4-Polymerization Solution 
400 ul of N, N-dimethyl-P-toludine: Sigm-Aldricha D18,900-6 [Steinheim; Germany] is added to 
100ml of cold (4°C) solution 3 and stirred for a few minutes.  
After addition of the accelerator care is taken that the mixture is kept cold at all times. 
Note: All resin solutions are stirred for at least 1 hour before use. It is essential that the methacrylate 
be kept completely dry. It should be stored in bottles containing a drying agent molecular sieve at 4°C. 
 
Reference: Embedding of bone samples in methacrylate: On improved method suitable for bone 













A-8.2.1-Tungsten Carbide Blade 
6-10 µm thick sections are prepared at room temperature with a Leica SM2500 sliding microtome 
equipped with a D-profile knife with a tungsten carbide cutting edge. During  sectioning  
the knife and the block are kept moist with 30% methanol. Sections are first floated onto 
30%methanol 
at 42°C in a water bath then onto 0.l% aqueous  Elmer's glue(Cat No:60308-Canada) at 42°C, picked 
up on coated slides (Marienfeld; Histobond; Germany), flattened with chloroform vapours, covered by 
a plastic film, flattened with a rubber roller. Press with a spring clamp and dry for 2 days at 42°C. 
A-8.2.2-Saw Ground Technique 
Resin blocks were removed from the plastic containers and prepared for sectioning. This involved 
trimming the block to the start of the tissue using the Buehler high-speed precision saw, polishing the 
block surface using two grades of water-paper, 600 and 1200 grit. Once dried, the blocks were glued 
onto coated glass slides using Elmers Ultimate Glue (USA), by placing a drop of glue onto the block  
and pressing it onto the slide. This was clamped and placed under weight overnight to ensure 
adherence. The following day the block was sectioned off the slide once again using the high-speed 
precision saw. The slide containing the thick section, was now polished down to obtain a thinner 
section. This was fine polished using the fine grit paper for the final section, ready for staining. These 
sections were stained without resin removal, by placing the slides into haematoxylin at 37°C fro 2 
hours, washing in tap water for 30 minutes and staining with Eosin for 30 seconds. No mounting was 
required. 
A-8.3-Deplasticization & Staining (Bladed Sections Only) 
1 2-methoxyehtylacetate (Aldrich-10,988-6) 20 min 20°C 
2 2-methoxyehtylacetate (Aldrich-10,988-6) 20 min 20°C 
3 2-methoxyehtylacetate (Aldrich-10,988-6) 20 min 20°C 
4 acetone [Merck-Gauteng; SA] 5 min 20°C 
5 acetone [Merck-Gauteng; SA] 5 min 20°C 
6 dist H2 5 min O 20°C 
7 dist H2 5 min O 20°C 
 












Following removal of the resin place sides into a coplin jar containing haemotoxylin  (Table A-4.1) at 
60°C for 1 hour. Rinse in running tap water for 40 minutes. Place slides on a hot plate at 60°C covered 
with 1% Eosin/Phloxine (Table A-4.2). Rinse and do not mount. 
A-8.3.2-Resin Immunofluorescence 
Following removal of resin apply relevant antigen retrieval depending on primary antibody used. For reisn 
sections Primary and secondary incubations are doubled, but otherwise the protocol is the same as (A-7.1). 
Depending on primary antibodies available, some antibodies are not possible on resin embedded tissue. 
A9. Transmission electron microscopy 
Alcian Blue Staining for Transmission Electron Microscopy. 
 Constituent Supplier 
A-9.1 Alcian Blue 8 GX Stock Sol [0.05%]  
 1 g alcian blue Merck-K24319334[Gauteng; SA] 
 100 ml acetone/milliQ water (9:1)  
A-9.2 Calcium Chloride Stock Sol 100ml  
 0.588 g calcium chloride [40mM] BDH-27586[Poole; UK] 
 100 ml milliQ water  
A-9.3 EDTA Stock Sol (pH 7.2-7.4) 100ml  
 0.292 g EDTA [10mM] Sigma-223 60 20 EM[Steinheim; Germany] 
 5 ml warm milliQ water  
 1 pellet sodium hydroxide Sigma-S8045 [Steinheim; Germany] 
A-9.4 HBSS 500ml  
 3.320 g sodium chloride [114mM] Sigma-S7653  [Steinheim; Germany] 
 0.375 g potassium chloride [10mM] Merck-AB004936-500 Gauteng; SA 
 0.081 g potassium dihydrogen ortho- 
phosphate[1.18mM] 
Merck-AB004873-500[Gauteng; SA] 
 0.144 g magnesium sulphate (7 H2
[1.17mM] 
O) BDH-10151 











 0.595 g HEPES [5mM] Sigma-H3375 [Steinheim; Germany] 
 0.5 g glucose [5.55mM] Sigma 
A-9.5 Magnesium Chloride Stock Sol  
 10.2 g magnesium chloride [30mM] Merck[Darmstsdt; Germany] 
 50 ml ultra-pure water  
A-9.6 McDowell Fixative  
 20 g para formaldehyde [4%w/v] Sigma-15,8127[Steinheim;Germany] 
 5.8 g sodium dihydrogen ortho-
phosphate H2
Merck-SAAR5822870 EM[Gauteng; SA] 
O[84mM] 
 20 ml gluteraldehyde [1%w/v] Aldrich- 
A-9.7 Toluidine Blue   
 1 g borax Sigma-719997[Steinheim; Germany] 
 1 g toluidine blue dye Merck-608 25 00 [Gauteng; SA] 
 
A-9.1-Alcian Blue 8 GX Stock Solution 
Add Alcian Blue to acetone/ultra-pure water mix. Stir for 1 hr at room temp in a closed vial. Pass 
through No. 589 filter paper. The residue is recovered from the paper and dried. Store in a dark place 
at room temperature. 
On the day of use, dissolve 150mg dried alcian blue powder in 25ml acidified ultra-pure water (180ml 
actenoe: 20ml Ultra-pure water) and pass through the following filters (5.0µm; 1.2 µm; 0.22µm;) 
A-9.2-Calcium Chloride Stock Sol 100ml  
Dissolve calcium chloride in ultra-pure water. 
A-9.3 EDTA-Stock Sol (pH 7.2-7.4) 100ml  
Dissolve EDTA in 50ml water together with sodium hydroxide. Adjust pH to 7.2-7.4 and make up to 
100ml with water. 
A-9.4-HBSS 500ml  
On the day of use, dissolve the salt components in 450ml ultra-pure water and add 6.25ml stcok CaCl2 
sol and 1.225ml EDTA stcok Sol. Adjust to 500ml and degas with air  (95% air; 5% CO2) for 1 hour 











A-9.5-Magnesium Chloride Stock Sol  
Dissolve MgCl2
A-9.6-McDowell Fixative  
 in water. 
Prepare in a fume hood to extract hazardous fumes. Dissolve parafomaldehyde in 250ml water at 
60°C. Add1-2 pellets of Sodium Hydroxide until solution is clear. Make up volume to 400ml with 
ultr-pure water. Add gluteraldehyde and NaH2PO4.H2
A-9.7-Toluidine Blue 
O. Adjust pH to 7.2-7.4 and store at 4°C. 
Mix all items together, stir and filter. 
A-9.8-Perfusion Fixation 
Rats are anaesthetized with Ketamine/Xlazine. A laparotomy is performed exposing the heart, and 
perfusion through the left ventricle using HBSS for 5 minutes at 8ml/minute. 
Perfuse using fixative alone, followed by 30 minutes of McDowell fixative containing alcian blue and 
MgCl2]
A-9.9-Post Fixation of tissue 
. The solution must be stirred constantly to prevent aggregation. The left and right carotid 
arteries were then dissected free and explanted, attached to the aorta, and placed in the McDowell 
fixative mixture overnight and stained as described below. 
The following day, tissue was fixed in 2% osmium for 1 to 2 hours in the fume hood and rinsed with 
distilled water for 5 minutes.  This was followed by staining with Uranyl Acetate for 2 hrs, with 
agitation and protection from light. And washed in ultra-pure water. 
A-9.9.1-Uranyl Acetate 
Constituent Supplier 
2% uranyl acetate dihydrate Merck-K2137273 (Darmstadt; Germany) 
50% ethanol Illovo [SA] 
Store the solution in a dark bottle at 4°C. 
A-9.9.2Lead citrate 
Constituent Supplier 
2.66 g lead nitrate Sigma-L6258 [Steinheim; Germany] 
3.52 g trisodium citrate Merck-582 25 00 EM [Gauteng; SA] 
60 ml distilled water  
16 ml of 10N sodium hydroxide(4 g in 100 ml distilled water) Sigma-S8045 [Steinheim; Germany] 











The solution was mixed and filtered before it was stored at 4°C. 
A-9.9.3-Sample preparation 
The tissue was dehydrated in each of the ethanol solutions for 15 minutes.  Firstly in 50% ethanol, 
70% ethanol, 80% ethanol, 90% ethanol and then two times for 20 minutes in 100% ethanol.  The 
tissue was then dehydrated twice in 100% acetone solutions for 20 minutes each.  
A-9.10-Spurr Resin Embeddibg 
Constituent Supplier 
Spurr Resin Kit TAAB-S032D [UK] 
The tissue was prepared for embedding in Spurr resin, as per kit intructions with different Spurr resin 
ratio solutions in acetone.  The tissue was placed in each solution for an hour at room temperature.  
The ratio’s (Spurr resin : Acetone) of the solutions were 1:2, 1:1 and 2:1. The last solution was 100% 
Spurr resin with two times for 1 hour at room temperature. The tissue was embedded in Spurr resin in 
a mould and allowed to polymerize overnight at 70°C.  
A-9.11-Sectioning and staining blocks for TEM 
Blocks were trimmed with a razor blade to expose the tissue from the block face and get rid of excess 
resin, thereby minimizing the surface cutting area. Semi-thin sections were cut using an Ultracut 
(Leica Ultracut ) microtome and a glass knife. Sections were mounted on glass slides, heat fixed and 
stained with toluidine blue for 3-5 mins in order to examine microscopically, to assess the correct area 
is being cut. Excess dye is rinsed off with distilled water, and the section viewed under light 
microscope. Ultra-thin sections were cut, sections picked up and placed onto copper grids. 
The tissue was stained with Uranyl Acetate for 10 minutes and afterwards with lead citrate for 2 
minutes.  After staining the grid was immersed in a drop of 10% aqua glacial acetic acid for 1 minute 
and rinsed in distilled water. The grid was ready for viewing on the TEM. 
A-9.12 Viewing TEM samples 
Samples were viewed on a Phillips EM420 Transmission Electron Microscope. Grids were placed in 
the viewing chamber, a vacuum was drawn and the image was located under low magnification (3500 
X), before going to a higher magnification and photographs were captured using an AnalySIS 
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